0000946644 2024-01-01 2024-09-30 0000946644 dei:BusinessContactMember 2024-01-01 2024-09-30 0000946644 2024-09-30 0000946644 2023-12-31 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2024-09-30 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2023-12-31 0000946644 AIM:SeriesBConvertiblePreferredStockMember 2024-09-30 0000946644 AIM:SeriesBConvertiblePreferredStockMember 2023-12-31 0000946644 2022-12-31 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2022-12-31 0000946644 AIM:SeriesBConvertiblePreferredStockMember 2022-12-31 0000946644 2024-07-01 2024-09-30 0000946644 2023-07-01 2023-09-30 0000946644 2023-01-01 2023-09-30 0000946644 2023-01-01 2023-12-31 0000946644 2022-01-01 2022-12-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000946644 us-gaap:CommonStockMember 2023-12-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000946644 us-gaap:RetainedEarningsMember 2023-12-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000946644 us-gaap:CommonStockMember 2024-03-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000946644 us-gaap:RetainedEarningsMember 2024-03-31 0000946644 2024-03-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000946644 us-gaap:CommonStockMember 2024-06-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000946644 us-gaap:RetainedEarningsMember 2024-06-30 0000946644 2024-06-30 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000946644 us-gaap:CommonStockMember 2022-12-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000946644 us-gaap:RetainedEarningsMember 2022-12-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000946644 us-gaap:CommonStockMember 2023-03-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000946644 us-gaap:RetainedEarningsMember 2023-03-31 0000946644 2023-03-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000946644 us-gaap:CommonStockMember 2023-06-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000946644 us-gaap:RetainedEarningsMember 2023-06-30 0000946644 2023-06-30 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2022-12-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2021-12-31 0000946644 us-gaap:CommonStockMember 2021-12-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000946644 us-gaap:RetainedEarningsMember 2021-12-31 0000946644 2021-12-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0000946644 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000946644 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000946644 2024-01-01 2024-03-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000946644 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000946644 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000946644 2024-04-01 2024-06-30 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000946644 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000946644 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000946644 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000946644 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000946644 2023-01-01 2023-03-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000946644 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000946644 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000946644 2023-04-01 2023-06-30 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000946644 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000946644 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000946644 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000946644 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000946644 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000946644 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000946644 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000946644 us-gaap:CommonStockMember 2024-09-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000946644 us-gaap:RetainedEarningsMember 2024-09-30 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0000946644 us-gaap:CommonStockMember 2023-09-30 0000946644 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000946644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000946644 us-gaap:RetainedEarningsMember 2023-09-30 0000946644 2023-09-30 0000946644 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2023-12-31 0000946644 srt:MinimumMember 2024-09-30 0000946644 srt:MaximumMember 2024-09-30 0000946644 us-gaap:PatentsMember 2024-09-30 0000946644 us-gaap:PatentsMember 2023-12-31 0000946644 us-gaap:TrademarksMember 2024-09-30 0000946644 us-gaap:TrademarksMember 2023-12-31 0000946644 us-gaap:PatentsMember 2022-12-31 0000946644 us-gaap:TrademarksMember 2022-12-31 0000946644 us-gaap:PatentsMember 2024-01-01 2024-09-30 0000946644 us-gaap:TrademarksMember 2024-01-01 2024-09-30 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2024-02-16 2024-02-16 0000946644 AIM:StreetervilleCapitalLlcMember AIM:NotePurchaseAgreementMember 2024-02-16 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2018-09-12 2018-09-12 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2018-09-12 0000946644 AIM:RestatedTwoThousandEighteenEquityIncentivePlanMember 2018-09-12 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2020-08-03 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2021-07-01 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2022-07-01 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2023-07-01 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2024-07-01 0000946644 AIM:TwoThousandEighteenEquityIncentivePlanMember 2024-09-30 0000946644 srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2018-01-01 2018-12-31 0000946644 2018-01-01 2018-12-31 0000946644 srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0000946644 2019-01-01 2019-12-31 0000946644 srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0000946644 srt:MinimumMember srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0000946644 srt:MaximumMember srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0000946644 srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0000946644 srt:MinimumMember srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0000946644 srt:MaximumMember srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0000946644 srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2022-01-01 2022-12-31 0000946644 srt:MinimumMember srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2022-01-01 2022-12-31 0000946644 srt:MaximumMember srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2022-01-01 2022-12-31 0000946644 srt:OfficerMember AIM:TwoThousandEighteenEquityIncentivePlanMember 2023-01-01 2023-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-09-30 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-01 2024-09-30 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-06-30 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-07-01 2024-09-30 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-09-30 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-06-30 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-07-01 2024-09-30 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-09-30 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-12-31 0000946644 AIM:EquityIncentivePlans2009Member 2022-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2009Member 2022-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2009Member 2022-12-31 0000946644 AIM:EquityIncentivePlans2009Member 2021-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2009Member 2021-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2009Member 2021-12-31 0000946644 AIM:EquityIncentivePlans2009Member 2023-01-01 2023-12-31 0000946644 AIM:EquityIncentivePlans2009Member 2022-01-01 2022-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2009Member 2023-01-01 2023-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2009Member 2023-01-01 2023-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2009Member 2022-01-01 2022-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2009Member 2022-01-01 2022-12-31 0000946644 AIM:EquityIncentivePlans2009Member 2023-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2009Member 2023-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2009Member 2023-12-31 0000946644 AIM:EquityIncentivePlans2018Member 2022-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2018Member 2022-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2018Member 2022-12-31 0000946644 AIM:EquityIncentivePlans2018Member 2021-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2018Member 2021-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2018Member 2021-12-31 0000946644 AIM:EquityIncentivePlans2018Member 2023-01-01 2023-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2018Member 2023-01-01 2023-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2018Member 2023-01-01 2023-12-31 0000946644 AIM:EquityIncentivePlans2018Member 2022-01-01 2022-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2018Member 2022-01-01 2022-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2018Member 2022-01-01 2022-12-31 0000946644 AIM:EquityIncentivePlans2018Member 2023-12-31 0000946644 srt:MinimumMember AIM:EquityIncentivePlans2018Member 2023-12-31 0000946644 srt:MaximumMember AIM:EquityIncentivePlans2018Member 2023-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-01-01 2021-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-01 2023-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-12-31 0000946644 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-12-31 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2023-05-10 0000946644 AIM:SeriesAJuniorParticipatingPreferredStockMember 2023-05-09 0000946644 us-gaap:RightsMember 2024-09-30 0000946644 us-gaap:RightsMember 2024-01-01 2024-09-30 0000946644 AIM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-09-30 0000946644 AIM:DirectorsOfficersAndEmployeesMember 2020-07-07 2020-07-07 0000946644 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000946644 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000946644 srt:MinimumMember us-gaap:CommonStockMember 2024-09-30 0000946644 srt:MaximumMember us-gaap:CommonStockMember 2024-09-30 0000946644 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000946644 srt:MinimumMember us-gaap:CommonStockMember 2023-09-30 0000946644 srt:MaximumMember us-gaap:CommonStockMember 2023-09-30 0000946644 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000946644 AIM:AllianceGlobalPartnersLLCMember 2019-09-26 2019-09-27 0000946644 AIM:AllianceGlobalPartnersLLCMember 2019-09-27 0000946644 AIM:WarrantsMember AIM:AllianceGlobalPartnersLLCMember 2019-09-27 0000946644 srt:MaximumMember AIM:RepresentativeWarrantsMember AIM:AllianceGlobalPartnersLLCMember 2019-09-27 0000946644 AIM:PreFundedWarrantsMember AIM:AllianceGlobalPartnersLLCMember 2019-09-27 0000946644 us-gaap:WarrantMember 2019-09-27 0000946644 AIM:PreFundedWarrantsMember 2019-09-27 0000946644 AIM:AllianceGlobalPartnersLLCMember 2019-09-25 2019-09-25 0000946644 AIM:PreFundedWarrantsMember 2020-01-01 2020-12-31 0000946644 us-gaap:WarrantMember 2020-01-01 2020-12-31 0000946644 srt:MaximumMember AIM:RepresentativeWarrantsMember AIM:AllianceGlobalPartnersLLCMember 2020-03-31 0000946644 2020-03-30 2020-03-31 0000946644 AIM:RepresentativeWarrantsMember AIM:AllianceGlobalPartnersLLCMember 2024-07-01 2024-09-30 0000946644 us-gaap:WarrantMember 2024-01-01 2024-09-30 0000946644 AIM:RepresentativeWarrantsMember AIM:AllianceGlobalPartnersLLCMember 2024-01-01 2024-09-30 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2023-04-19 2023-04-19 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2023-01-01 2023-12-31 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2024-07-01 2024-09-30 0000946644 AIM:EquityDistributionAgreementMember AIM:MaximGroupLLCMember 2024-01-01 2024-09-30 0000946644 us-gaap:CommonStockMember AIM:PurchaseAndRegistrationRightsAgreementMember AIM:AtlasSciencesLlcMember 2024-03-28 2024-03-28 0000946644 AIM:PurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-03-28 0000946644 AIM:PurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-03-28 2024-03-28 0000946644 AIM:AtlasSciencesLlcMember AIM:PurchaseAgreementMember 2024-03-28 0000946644 AIM:PurchaseAgreementMember 2024-04-01 2024-04-30 0000946644 AIM:PurchaseAgreementMember AIM:AtlasSciencesLlcMember 2024-04-01 2024-04-30 0000946644 AIM:PurchaseAgreementMember 2024-01-01 2024-09-30 0000946644 us-gaap:CommonStockMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 2024-06-03 0000946644 us-gaap:CommonStockMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 0000946644 us-gaap:WarrantMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 2024-06-03 0000946644 us-gaap:WarrantMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 0000946644 AIM:ClassBCommonWarrantMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 2024-06-03 0000946644 AIM:ClassBCommonWarrantMember AIM:SecuritiesPurchaseAgreementMember 2024-06-03 0000946644 AIM:PlacementAgentMember 2024-05-01 2024-05-31 0000946644 AIM:BoardMember 2023-12-31 0000946644 us-gaap:RightsMember 2023-12-31 0000946644 us-gaap:RightsMember AIM:SeriesBConvertiblePreferredStockMember 2023-12-31 0000946644 us-gaap:WarrantMember 2023-12-31 0000946644 us-gaap:RightsMember 2023-01-01 2023-12-31 0000946644 AIM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-12-31 0000946644 us-gaap:PreferredStockMember 2023-12-31 0000946644 AIM:DirectorsOfficersAndEmployeesMember 2020-07-06 2020-07-07 0000946644 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000946644 srt:MinimumMember us-gaap:CommonStockMember 2023-12-31 0000946644 srt:MaximumMember us-gaap:CommonStockMember 2023-12-31 0000946644 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000946644 srt:MinimumMember us-gaap:CommonStockMember 2022-12-31 0000946644 srt:MaximumMember us-gaap:CommonStockMember 2022-12-31 0000946644 AIM:MaximGroupLLCMember 2023-04-18 2023-04-19 0000946644 AIM:MaximGroupLLCMember 2023-01-01 2023-12-31 0000946644 AIM:MaximGroupLLCMember 2023-12-31 0000946644 us-gaap:SubsequentEventMember AIM:MaximGroupLLCMember 2024-01-01 2024-01-01 0000946644 us-gaap:SubsequentEventMember AIM:MaximGroupLLCMember 2024-01-01 0000946644 AIM:EquityIncentivePlanTwoThousandNineMember 2018-09-12 0000946644 AIM:EquityIncentivePlanTwoThousandNineMember 2018-09-12 2018-09-12 0000946644 AIM:EmployeesMember 2023-01-01 2023-12-31 0000946644 AIM:EmployeesMember 2022-01-01 2022-12-31 0000946644 AIM:NonEmployeeMember 2023-01-01 2023-12-31 0000946644 AIM:NonEmployeeMember 2022-01-01 2022-12-31 0000946644 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0000946644 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember 2023-01-01 2023-12-31 0000946644 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassAWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassAWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassAWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassAWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassAWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassAWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassAWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassAWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassAWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassAWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassAWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassBWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputSharePriceMember AIM:ClassBWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassBWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputExercisePriceMember AIM:ClassBWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassBWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputRiskFreeInterestRateMember AIM:ClassBWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputExpectedTermMember AIM:ClassBWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassBWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputPriceVolatilityMember AIM:ClassBWarrantMember 2023-12-31 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassBWarrantMember 2024-09-30 0000946644 us-gaap:MeasurementInputExpectedDividendRateMember AIM:ClassBWarrantMember 2023-12-31 0000946644 srt:MinimumMember 2023-01-01 2023-12-31 0000946644 srt:WeightedAverageMember 2023-01-01 2023-12-31 0000946644 srt:MaximumMember 2023-01-01 2023-12-31 0000946644 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000946644 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000946644 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000946644 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000946644 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000946644 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000946644 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000946644 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000946644 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000946644 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000946644 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000946644 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000946644 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000946644 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000946644 srt:MinimumMember 2024-01-01 2024-09-30 0000946644 srt:MaximumMember 2024-01-01 2024-09-30 0000946644 srt:MinimumMember 2023-12-31 0000946644 srt:MaximumMember 2023-12-31 0000946644 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0000946644 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000946644 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0000946644 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0000946644 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000946644 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000946644 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0000946644 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0000946644 AIM:ClinicalStudiesMember 2024-07-01 2024-09-30 0000946644 AIM:ManufacturingAndEngineeringMember 2024-07-01 2024-09-30 0000946644 AIM:QualityControlMember 2024-07-01 2024-09-30 0000946644 AIM:RegulatoryMember 2024-07-01 2024-09-30 0000946644 AIM:ClinicalStudiesMember 2023-07-01 2023-09-30 0000946644 AIM:ManufacturingAndEngineeringMember 2023-07-01 2023-09-30 0000946644 AIM:QualityControlMember 2023-07-01 2023-09-30 0000946644 AIM:RegulatoryMember 2023-07-01 2023-09-30 0000946644 AIM:ClinicalStudiesMember 2024-01-01 2024-09-30 0000946644 AIM:ManufacturingAndEngineeringMember 2024-01-01 2024-09-30 0000946644 AIM:QualityControlMember 2024-01-01 2024-09-30 0000946644 AIM:RegulatoryMember 2024-01-01 2024-09-30 0000946644 AIM:ClinicalStudiesMember 2023-01-01 2023-09-30 0000946644 AIM:ManufacturingAndEngineeringMember 2023-01-01 2023-09-30 0000946644 AIM:QualityControlMember 2023-01-01 2023-09-30 0000946644 AIM:RegulatoryMember 2023-01-01 2023-09-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2024-07-01 2024-09-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2023-07-01 2023-09-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2024-01-01 2024-09-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2023-01-01 2023-09-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2022-04-01 2022-04-30 0000946644 AIM:AdvancedPancreaticCancerStudyAgreementMember AIM:AmarexClinicalResearchLLCMember 2024-07-01 2024-09-30 0000946644 AIM:AdvancedPancreaticCancerStudyAgreementMember AIM:AmarexClinicalResearchLLCMember 2023-07-01 2023-09-30 0000946644 AIM:AdvancedPancreaticCancerStudyAgreementMember AIM:AmarexClinicalResearchLLCMember 2024-01-01 2024-09-30 0000946644 AIM:AdvancedPancreaticCancerStudyAgreementMember AIM:AmarexClinicalResearchLLCMember 2023-01-01 2023-09-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2022-09-01 2022-09-30 0000946644 AIM:AmarexClinicalResearchLLCMember 2023-01-01 2023-12-31 0000946644 AIM:PostCOVIDStudyAgreementMember AIM:AmarexClinicalResearchLLCMember 2024-07-01 2024-09-30 0000946644 AIM:PostCOVIDStudyAgreementMember AIM:AmarexClinicalResearchLLCMember 2023-07-01 2023-09-30 0000946644 AIM:PostCOVIDStudyAgreementMember AIM:AmarexClinicalResearchLLCMember 2024-01-01 2024-09-30 0000946644 AIM:PostCOVIDStudyAgreementMember AIM:AmarexClinicalResearchLLCMember 2023-01-01 2023-09-30 0000946644 AIM:JubilantHollisterStierMember 2017-01-01 2017-12-31 0000946644 AIM:JubilantHollisterStierMember 2023-01-01 2023-12-31 0000946644 AIM:AmpligenManufacturingAgreementMember AIM:JubilantHollisterStierMember 2024-07-01 2024-09-30 0000946644 AIM:AmpligenManufacturingAgreementMember AIM:JubilantHollisterStierMember 2023-07-01 2023-09-30 0000946644 AIM:AmpligenManufacturingAgreementMember AIM:JubilantHollisterStierMember 2024-01-01 2024-09-30 0000946644 AIM:AmpligenManufacturingAgreementMember AIM:JubilantHollisterStierMember 2023-01-01 2023-09-30 0000946644 AIM:MasterServiceAgreementAndQualityAgreementMember AIM:SterlingPharmaSolutionsMember 2024-07-01 2024-09-30 0000946644 AIM:MasterServiceAgreementAndQualityAgreementMember AIM:SterlingPharmaSolutionsMember 2023-07-01 2023-09-30 0000946644 AIM:MasterServiceAgreementAndQualityAgreementMember AIM:SterlingPharmaSolutionsMember 2024-01-01 2024-09-30 0000946644 AIM:MasterServiceAgreementAndQualityAgreementMember AIM:SterlingPharmaSolutionsMember 2023-01-01 2023-09-30 0000946644 AIM:JointClinicalStudyAgreementMember AIM:ErasmusUniversityMedicalCenterMember 2023-04-01 2023-04-30 0000946644 AIM:JointClinicalStudyAgreementMember AIM:ErasmusUniversityMedicalCenterMember 2024-07-01 2024-09-30 0000946644 AIM:JointClinicalStudyAgreementMember AIM:ErasmusUniversityMedicalCenterMember 2023-07-01 2023-09-30 0000946644 AIM:JointClinicalStudyAgreementMember AIM:ErasmusUniversityMedicalCenterMember 2024-01-01 2024-09-30 0000946644 AIM:JointClinicalStudyAgreementMember AIM:ErasmusUniversityMedicalCenterMember 2023-01-01 2023-09-30 0000946644 AIM:ConsultingAgreementMember AIM:AzenovaLLCMember 2023-10-31 0000946644 AIM:ConsultingAgreementMember AIM:AzenovaLLCMember 2024-08-01 2024-08-31 0000946644 AIM:ConsultingAgreementMember AIM:AzenovaLLCMember 2024-07-01 2024-09-30 0000946644 AIM:ConsultingAgreementMember AIM:AzenovaLLCMember 2023-07-01 2023-09-30 0000946644 AIM:ConsultingAgreementMember AIM:AzenovaLLCMember 2024-01-01 2024-09-30 0000946644 AIM:ConsultingAgreementMember AIM:AzenovaLLCMember 2023-01-01 2023-09-30 0000946644 AIM:AlcamiCorporationMember 2023-09-01 2023-09-30 0000946644 AIM:AlcamiCorporationMember 2023-07-01 2023-09-30 0000946644 AIM:AlcamiCorporationMember 2024-01-01 2024-09-30 0000946644 AIM:AlcamiCorporationMember 2023-01-01 2023-09-30 0000946644 AIM:ClinicalStudiesMember 2023-01-01 2023-12-31 0000946644 AIM:ManufacturingAndEngineeringMember 2023-01-01 2023-12-31 0000946644 AIM:QualityControlMember 2023-01-01 2023-12-31 0000946644 AIM:RegulatoryMember 2023-01-01 2023-12-31 0000946644 AIM:ClinicalStudiesMember 2022-01-01 2022-12-31 0000946644 AIM:ManufacturingAndEngineeringMember 2022-01-01 2022-12-31 0000946644 AIM:QualityControlMember 2022-01-01 2022-12-31 0000946644 AIM:RegulatoryMember 2022-01-01 2022-12-31 0000946644 AIM:AmarexClinicalResearchLLCMember 2022-01-01 2022-12-31 0000946644 AIM:PancreaticCancerMember AIM:AmarexClinicalResearchLLCMember 2023-01-01 2023-12-31 0000946644 AIM:PancreaticCancerMember AIM:AmarexClinicalResearchLLCMember 2022-01-01 2022-12-31 0000946644 AIM:PostCOVIDMember AIM:AmarexClinicalResearchLLCMember 2023-01-01 2023-12-31 0000946644 AIM:PostCOVIDMember AIM:AmarexClinicalResearchLLCMember 2022-01-01 2022-12-31 0000946644 AIM:JubilantHollisterStierMember 2023-01-01 2023-03-31 0000946644 AIM:JubilantHollisterStierMember 2023-03-31 0000946644 AIM:ResearchConsultingAndSupplyAgreementsMember AIM:JubilantHollisterStierMember 2023-01-01 2023-12-31 0000946644 AIM:ResearchConsultingAndSupplyAgreementsMember AIM:JubilantHollisterStierMember 2022-01-01 2022-12-31 0000946644 AIM:MasterServiceAgreementAndQualityAgreementMember AIM:PharmaSolutionsMember 2023-01-01 2023-12-31 0000946644 AIM:JointClinicalStudyAgreementMember AIM:ErasmusMember 2022-12-01 2022-12-31 0000946644 AIM:JjointClinicalStudyAgreementMember AIM:ErasmusMember 2023-01-01 2023-12-31 0000946644 AIM:AzenovaSalesInternationalMember 2023-10-31 0000946644 AIM:AzenovaSalesInternationalMember 2023-01-01 2023-12-31 0000946644 AIM:AlcamiMember 2023-09-01 2023-09-30 0000946644 AIM:AlcamiMember 2023-01-01 2023-12-31 0000946644 AIM:AlcamiMember 2022-01-01 2022-12-31 0000946644 us-gaap:CommonStockMember us-gaap:SubsequentEventMember AIM:SecuritiesPurchaseAgreementMember 2024-10-01 2024-10-01 0000946644 us-gaap:CommonStockMember us-gaap:SubsequentEventMember AIM:SecuritiesPurchaseAgreementMember 2024-10-01 0000946644 AIM:ClassCCommonWarrantMember us-gaap:SubsequentEventMember AIM:SecuritiesPurchaseAgreementMember 2024-10-01 2024-10-01 0000946644 AIM:ClassCCommonWarrantMember us-gaap:SubsequentEventMember AIM:SecuritiesPurchaseAgreementMember 2024-10-01 0000946644 AIM:ClassDCommonWarrantMember us-gaap:SubsequentEventMember AIM:SecuritiesPurchaseAgreementMember 2024-10-01 2024-10-01 0000946644 AIM:ClassDCommonWarrantMember us-gaap:SubsequentEventMember AIM:SecuritiesPurchaseAgreementMember 2024-10-01 0000946644 us-gaap:SubsequentEventMember 2024-10-01 2024-10-01 0000946644 AIM:UnsecuredPromissoryNoteMember us-gaap:NonrelatedPartyMember us-gaap:SubsequentEventMember 2024-02-16 2024-02-16 0000946644 us-gaap:NonrelatedPartyMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-28 2024-03-28 0000946644 AIM:EmployeesPurchasePlanMember us-gaap:SubsequentEventMember 2024-03-01 2024-03-31 0000946644 AIM:DirectorsPurchasePlanMember us-gaap:SubsequentEventMember 2024-03-01 2024-03-31 0000946644 AIM:EmployeesPurchasePlanMember us-gaap:SubsequentEventMember 2024-03-31 0000946644 AIM:DirectorsPurchasePlanMember us-gaap:SubsequentEventMember 2024-03-31 0000946644 2021-01-01 2021-12-31 0000946644 AIM:PatentAndTrademarkRightsMember 2023-12-31 0000946644 AIM:MutualFundsMember 2023-12-31 0000946644 AIM:MutualFundsMember 2022-12-31 0000946644 AIM:EquityIncentivePlanTwoThousandNineMember 2023-01-01 2023-12-31 0000946644 AIM:EquityIncentivePlansTwoThousandAndEighteenMember 2023-01-01 2023-12-31 0000946644 srt:MinimumMember 2022-01-01 2022-12-31 0000946644 srt:MaximumMember 2022-01-01 2022-12-31 0000946644 us-gaap:WarrantMember 2022-12-31 0000946644 srt:MinimumMember us-gaap:WarrantMember 2022-12-31 0000946644 srt:MaximumMember us-gaap:WarrantMember 2022-12-31 0000946644 us-gaap:WarrantMember 2021-12-31 0000946644 srt:MinimumMember us-gaap:WarrantMember 2021-12-31 0000946644 srt:MaximumMember us-gaap:WarrantMember 2021-12-31 0000946644 us-gaap:WarrantMember 2023-01-01 2023-12-31 0000946644 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000946644 us-gaap:WarrantMember 2023-12-31 0000946644 srt:MinimumMember us-gaap:WarrantMember 2023-12-31 0000946644 srt:MaximumMember us-gaap:WarrantMember 2023-12-31 0000946644 srt:MinimumMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0000946644 srt:MaximumMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0000946644 AIM:FourZeroOnekPlanMember 2023-01-01 2023-12-31 0000946644 AIM:NamedExecutiveOfficersMember AIM:EmploymentContractualAgreementsMember 2023-01-01 2023-12-31 0000946644 AIM:NamedExecutiveOfficersMember AIM:EmploymentContractualAgreementsMember 2022-01-01 2022-12-31 0000946644 AIM:NamedExecutiveOfficersMember AIM:EmploymentContractualAgreementsMember 2023-12-31 0000946644 AIM:NamedExecutiveOfficersMember AIM:EmploymentContractualAgreementsMember 2022-12-31 0000946644 AIM:ThomasKEquelsMember AIM:StockOptionsMember AIM:EmploymentAgreementMember 2023-01-01 2023-12-31 0000946644 AIM:PeterRodinoMember AIM:StockOptionsMember AIM:EmploymentAgreementMember 2023-01-01 2023-12-31 0000946644 AIM:EquelsandRodinoMember 2023-01-01 2023-12-31 0000946644 AIM:ThomasKEquelsMember AIM:StockOptionsMember AIM:EmploymentAgreementMember 2022-01-01 2022-12-31 0000946644 AIM:PeterRodinoMember AIM:StockOptionsMember AIM:EmploymentAgreementMember 2022-01-01 2022-12-31 0000946644 srt:MinimumMember AIM:PeterRodinoMember AIM:StockOptionsMember AIM:EmploymentAgreementMember 2022-01-01 2022-12-31 0000946644 srt:MaximumMember AIM:PeterRodinoMember AIM:StockOptionsMember AIM:EmploymentAgreementMember 2022-01-01 2022-12-31 0000946644 AIM:EllenLintalMember AIM:StockOptionsMember AIM:EmploymentAgreementMember 2022-01-01 2022-12-31 0000946644 AIM:EquelsRodinoAndFormerOfficerLintalMember 2023-01-01 2023-12-31 0000946644 us-gaap:DomesticCountryMember 2023-12-31 0000946644 us-gaap:NewJerseyDivisionOfTaxationMember 2023-12-31 0000946644 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0000946644 country:BE 2023-12-31 0000946644 stpr:NJ 2023-12-31 0000946644 stpr:NJ 2023-01-01 2023-12-31 0000946644 stpr:NJ 2022-01-01 2022-12-31 0000946644 srt:RestatementAdjustmentMember 2022-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember 2023-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember 2022-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000946644 AIM:MarchTwoThousandNineteenWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 iso4217:USD shares iso4217:USD shares pure AIM:Integer true 0000946644 S-1/A

P3Y

P10Y

AMENDMENT NO. 1 AIM ImmunoTech Inc. DE 52-0845822 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 Thomas K. Equels 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 Non-accelerated Filer true false

915000

5439000

6287000

7631000

1184000

368000

302000

7570000

14556000

117000

127000

653000

697000

2532000

2313000

2716000

1688000

13588000

19381000

6264000

6443000

1011000

1986000

232000

223000

2593000

10100000

8652000

437000

495000

139000

10676000

9147000

0.001

4000000

250000

1000 1000

10000

689

689000

0.001

350000000

58668647

49102484

59000

49000

423714000

419004000

-420861000

-409508000

2912000

10234000

13588000

19381000

35000

46000

125000

137000

35000

46000

125000

137000

8000

30000

24000

30000

1437000

2734000

4533000

7739000

3079000

5439000

9485000

10280000

4524000

8203000

14042000

18049000

-4489000

-8157000

-13917000

-17912000

273000

-310000

96000

-201000

718000

294000

3379000

811000

202000

453000

39000

16000

-458000 318000 900000

-3700000

-7816000

-11353000

-16386000

-0.06

-0.16

-0.21

-0.34

57677016

48635165

53351467

48483802

689000

49102484

49000

419004000

-409508000

10234000

807577

1000

328000

329000

3272

80000

338600

-5817000

689000

50251933

50000

419412000

-415325000

4826000

6884747

7000

525000

532000

2500000

80000

-689000 689000

-1836000

57136680

57000

423206000

-417161000

6102000

653430

1000

179000

180000

878537

1000

329000

330000

-3700000

58668647

59000

423714000

-420861000

2912000

696000

48084287

48000

418270000

-380546000

38468000

322583

100000

82000

-4000

456

4000

-3661000

692000

48407326

48000

418456000

-384207000

34989000

11937

5000

50000

-2000

228

2000

-4909000

690000

48419491

48000

418513000

-389116000

30135000

690000

48419491

48000

418513000

-389116000

30135000

377959

233000

50000

-7816000

690000

48797450

48000

418796000

-396932000

22602000

690000

48797450

48000

418796000

-396932000

22602000

-11353000

-16386000

28000

30000

46000 14000

154000

150000

226000 151000 900000

490000

182000

95000

-201000

-458000

232000

9000

-1181000

-1676000

63000

-192000

-231000

-136000

1028000

-179000

2411000

-799000

915000

-10933000

-11509000

1597000

924000

158000

1155000

18000

10000

419000

377000

1002000

-618000

860000

338000

2500000

2047000

5407000

338000

-4524000

-11789000

5439000

27053000

915000

15264000

-3000 49000 373000 -71000 6000 175000

Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are an immuno-pharma company headquartered in Ocala, Florida, focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved by the FDA or marketed in the United States but is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). The Company is currently proceeding primarily in four areas: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluating Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or the Post-COVID condition of fatigue.</td></tr></table> The Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (“EMA”), which trials support a potential future NDA. However, AIM’s antiviral experimentation is designed to accumulate additional preliminary data supporting the hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, AIM will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data, including foreign venues. AIM’s business plan requires one or more Contract Manufacturing Organizations (“CMO”) to produce Ampligen and its Active Pharmaceutical Ingredients (APIs). This includes utilizing Jubilant HollisterStier and Sterling for the manufacture of Ampligen and our Poly I and Poly C12U polynucleotides, respectively. In the opinion of management, all adjustments necessary for a fair presentation of its consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2023, and 2022, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed on April 1, 2024. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals. Liquidity and Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Pursuant to the requirements of the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt about the Company’s ability to continue as a going concern exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company’s principal source of liquidity is its cash and cash equivalents, marketable securities, and proceeds from financing activities to provide the necessary funding to meet our obligations as they become due. The Company has suffered losses from operations and net cash used on operating activities for the nine-month period ended September 30, 2024, and has a working capital deficit as of September 30, 2024. Additionally, the Company’s stockholders’ equity was below the minimum requirements for continued listing on the New York Stock Exchange American (“NYSE American”). These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. Management evaluated the conditions, and the significance of these conditions related to the Company’s ability to meet its obligations and determined that the primary cause of the deficit was related to certain accounts payable which the Company is currently in negotiations with the vendor. These negotiations are ongoing and could result in significant amounts which could partially alleviate the negative working capital. There is no assurance as to the timing or outcome of these efforts. If the Company is unable to implement sufficient mitigation efforts, the Company may be forced to limit its business activities or be unable to continue as a going concern, which would have a material adverse effect on its results of operations and financial condition.

Note 2: Cash and Cash Equivalents Cash includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the nine months ended September 30, 2024, some accounts held at financial institutions were in excess of the federally insured limit of $250,000. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.

250000

<p id="xdx_80E_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zFfeajKKv4L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Note 3: Marketable Securities Marketable securities consist of mutual funds. At September 30, 2024 and December 31, 2023, it was determined that none of the marketable securities had an other-than-temporary impairment. At September 30, 2024 and December 31, 2023, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 12: Fair Value). At September 30, 2024, and December 31, 2023 the Company held $6,287,000 and $7,631,000 respectively, in mutual funds. Mutual Funds classified as available for sale consisted of $6,287,000 at September 30, 2024. The net gain recognized for the three-month period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September 30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September 30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30, 2024 on equity securities still held was $373,000. Mutual Funds classified as available for sale consisted of $7,631,000 at December 31, 2023. The net loss recognized for the three-month period ended September 30, 2023 on equity securities was ($309,000). The net losses recognized for the three-month period ended September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month period ended September 30, 2023 on equity securities still held was ($71,000).

6287000

7631000

6287000

The net gain recognized for the three-month period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September 30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September 30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30, 2024 on equity securities still held was $373,000.

7631000

The net loss recognized for the three-month period ended September 30, 2023 on equity securities was ($309,000). The net losses recognized for the three-month period ended September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month period ended September 30, 2023 on equity securities still held was ($71,000).

Note 4: Property and Equipment, net Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_494_20240930_z5hFwuCCDQ9f" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_49B_20231231_zBpvQnD47La7" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENztUG_zMy3sLzXGS6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Furniture, fixtures, and equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,448</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENztUG_zQo49N7TPXn1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,349</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,321</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENztUG_zFFesyhVHXMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to ten years. Depreciation expense for the nine months ending September 30, 2024 and September 30, 2023 was $28,000 and $30,000, respectively.

Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_494_20240930_z5hFwuCCDQ9f" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_49B_20231231_zBpvQnD47La7" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENztUG_zMy3sLzXGS6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Furniture, fixtures, and equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,448</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENztUG_zQo49N7TPXn1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,349</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,321</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENztUG_zFFesyhVHXMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1466000

1448000

1349000

1321000

117000

127000

P10Y

28000

30000

Note 5: Patents, and Trademark Rights, Net Patent and trademark rights consist of the following (in thousands): Schedule of Patent and Trademark Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td> </td><td> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Gross Carrying Value</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated Amortization</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net Carrying Value</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Gross Carrying Value</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated Amortization</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net Carrying Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbUICxw1Xj8c" style="width: 8%; text-align: right" title="Gross carrying value">3,315</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zpwzsHMhXvG4" style="width: 8%; text-align: right" title="Accumulated amortization">(887</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zEPpi2tMxpDa" style="width: 8%; text-align: right" title="Net carrying value">2,428</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxSZR35aLli" style="width: 8%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8J54CytraFk" style="width: 8%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAGxijkjvRf" style="width: 8%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Trademarks</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zvfvEdCm6oY3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">232</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z33LHiL2D1bg" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(128</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQvo28Jaoe61" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">104</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zjJM7f8pmrPd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">229</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zoBAV3VSrXfk" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSX6Kv6qQrbl" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">116</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net amortizable patents and trademarks rights</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zwH2Yy8CWW62" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,547</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zxHNsNce0g53" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(1,015</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zUBZJdMlSL8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,532</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zXvptjERIbih" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zheFoTKFHNB6" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zL8AbrNZtT67" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="text-align: left"> </td></tr> </table> Patent and trademark rights acquisitions, abandonments and amortization: Schedule of Changes in Patents, Trademark Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20240101__20240930_zYazcw4FAWm1" style="width: 20%; text-align: right" title="Balance">2,313</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquisitions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20240930_zQkkLOeVr6Pl" style="text-align: right" title="Acquisitions">419</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Abandonments and expirations</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20240101__20240930_z1PWeAKfCbvg" style="text-align: right" title="Abandonments">(46</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20240101__20240930_zbcdeHtCc1fd" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization">(154</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20240101__20240930_zCEi51a2i4Qc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">2,532</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over an estimated useful life of 17 years for patents and 10 years for trademarks. The weighted remaining average amortization period is approximately <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_c20240101__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvpKWnMvDxb4">12 years for patents and <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_c20240101__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVS9hQqXWWUe">6 years for trademarks, respectively. The company expenses annuity costs related to its trademarks and patents. Amortization of patents and trademarks for each of the next five years and thereafter is as follows (in thousands): Schedule of Amortization of Patents and Trademarks <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Year Ending December 31,</td><td> </td> <td colspan="2" id="xdx_491_20240930_z1tIYpVuM4Xe" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zwjhISSXC6c7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right">72</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zS5vaVk3aZUc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Remainder year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_z0D1XARE1Qpc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">268</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zTsNY3ua6BM7" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year one</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">268</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zOxvNUb4gXL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zoOVx8HtnVqi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_z8CSoy1bq7W3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zd5hADRcvfP4" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zzeP7Z5w3dp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zrSd1XdSTIfk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zgNxxRprvzIc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year five</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zo0tQ47aEpWk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,469</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zSOT8Ifpkzkc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Year six</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,469</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zIW8CpphyCig" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Year seven</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zWhqaolA3oN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,532</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Patent and trademark rights consist of the following (in thousands): Schedule of Patent and Trademark Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td> </td><td> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Gross Carrying Value</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated Amortization</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net Carrying Value</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Gross Carrying Value</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated Amortization</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net Carrying Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbUICxw1Xj8c" style="width: 8%; text-align: right" title="Gross carrying value">3,315</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zpwzsHMhXvG4" style="width: 8%; text-align: right" title="Accumulated amortization">(887</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zEPpi2tMxpDa" style="width: 8%; text-align: right" title="Net carrying value">2,428</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxSZR35aLli" style="width: 8%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8J54CytraFk" style="width: 8%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAGxijkjvRf" style="width: 8%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Trademarks</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zvfvEdCm6oY3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">232</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z33LHiL2D1bg" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(128</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQvo28Jaoe61" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">104</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zjJM7f8pmrPd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">229</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zoBAV3VSrXfk" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSX6Kv6qQrbl" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">116</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net amortizable patents and trademarks rights</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zwH2Yy8CWW62" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,547</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zxHNsNce0g53" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(1,015</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zUBZJdMlSL8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,532</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zXvptjERIbih" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zheFoTKFHNB6" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zL8AbrNZtT67" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="text-align: left"> </td></tr> </table>

3315000

-887000

2428000

2947000

-750000

2197000

232000

-128000

104000

229000

-113000

116000

3547000

-1015000

2532000

3176000

-863000

2313000

Patent and trademark rights acquisitions, abandonments and amortization: Schedule of Changes in Patents, Trademark Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20240101__20240930_zYazcw4FAWm1" style="width: 20%; text-align: right" title="Balance">2,313</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquisitions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20240930_zQkkLOeVr6Pl" style="text-align: right" title="Acquisitions">419</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Abandonments and expirations</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20240101__20240930_z1PWeAKfCbvg" style="text-align: right" title="Abandonments">(46</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20240101__20240930_zbcdeHtCc1fd" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization">(154</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20240101__20240930_zCEi51a2i4Qc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">2,532</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2313000

419000

46000

154000

2532000

P17Y

P10Y

P12Y

P6Y

Amortization of patents and trademarks for each of the next five years and thereafter is as follows (in thousands): Schedule of Amortization of Patents and Trademarks <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Year Ending December 31,</td><td> </td> <td colspan="2" id="xdx_491_20240930_z1tIYpVuM4Xe" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zwjhISSXC6c7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right">72</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zS5vaVk3aZUc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Remainder year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_z0D1XARE1Qpc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">268</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zTsNY3ua6BM7" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year one</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">268</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zOxvNUb4gXL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zoOVx8HtnVqi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_z8CSoy1bq7W3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zd5hADRcvfP4" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zzeP7Z5w3dp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zrSd1XdSTIfk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zgNxxRprvzIc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year five</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zo0tQ47aEpWk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,469</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zSOT8Ifpkzkc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Year six</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,469</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zIW8CpphyCig" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Year seven</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zWhqaolA3oN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,532</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

72000

268000

265000

239000

219000

1469000 1469000

2532000

Note 6: Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_493_20240930_zpvTaGPeAyEl" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_492_20231231_zyfNm3w9hjBi" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zxZUuEaIXWSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">414</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zErRAiIuwHzd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">790</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,352</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z8kZCQ7m4g52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Clinical trial expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zxpeMg9SgGIi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ziLMURobsHek" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zFlkF5q6M6L8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,011</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Accrued expenses consist of the following: Schedule of Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_493_20240930_zpvTaGPeAyEl" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_492_20231231_zyfNm3w9hjBi" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zxZUuEaIXWSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">414</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zErRAiIuwHzd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">790</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,352</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z8kZCQ7m4g52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Clinical trial expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zxpeMg9SgGIi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ziLMURobsHek" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zFlkF5q6M6L8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,011</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1000

414000

790000

1352000

132000 184000

51000

37000

36000

1011000

1986000

Note 7: Unsecured Promissory Note On February 16, 2024, the Company (“Borrower”) entered into a Note Purchase Agreement with Streeterville Capital LLC (“Streeterville” or the “Lender”). Under the terms of the agreement, Streeterville paid the Company $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zWAjx8pvr3e9">2,500,000 in exchange for an unsecured promissory Note with an Original Issue Discount of $<span id="xdx_900_eus-gaap--DebtConversionOriginalDebtAmount1_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zSDdVIlvnB4a">781,250. The Company will pay $3,301,250 consisting of the principal amount of the Note, together with the original issue discount and $<span id="xdx_901_eus-gaap--DeferredFinanceCostsGross_iI_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zqKMVPANOnc3">20,000 of lender transaction fees, no later than February 16, 2026. The stated interest rate of the note is <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_z7D8T6ZrVfm3">10%. There was no debt at December 31, 2023. <p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_z8qR51yTaila" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Schedule of Long Term Debt <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240930_znIPEbSifguf" style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Debt schedule at September 30, 2024 (in thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: right"></td><td style="padding-bottom: 1pt"> </td> </tr> <tr id="xdx_40F_eus-gaap--LongTermDebt_iI_pn3n3_z5Qzrbi8hhlh" style="vertical-align: bottom; background-color: White"> <td style="width: 77%; text-align: left">Long-term debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">3,301</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zme2jc2Cl9lc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unamortized Original issue discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(555</td><td style="text-align: left">)</td> </tr> <tr id="xdx_40C_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zEzzylzYJd6g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14</td><td style="padding-bottom: 1pt; text-align: left">)</td> </tr> <tr id="xdx_400_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_z1sjpi9zFbp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unamortized discount and debt issuance costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,732</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_z3tDTtSH1sf1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less current portion of long-term debt, net </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,593</td><td style="padding-bottom: 1pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zfrhvPyY2899" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table> Interest expense related to long-term debt was $226,000 at September 30, 2024. Amortization expenses related to long-term debt was $232,000 at September 30, 2024. This consisted of $226,000 in original issue discount and $6,000 for loan fee amortization. Future maturities of long-term debt at September 30, 2024 were $750,000 for fiscal years ending December 31, 2024 and $2,551,000 for fiscal years ending December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Current portion of long-term debt of approximately $3,000,000 is net of the current portion of debt discount of approximately $397,000 and the current portion of debt origination costs of approximately $10,000 as of September 30, 2024.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Long-term portion of debt of approximately $301,000 is net of the long-term portion of debt discount of approximately $159,000 and the unamortized debt origination costs of approximately $3,000 as of September 30, 2024.</td></tr></table> Current portion of long-term debt of approximately $3,000,000 is net of the current portion of debt discount of approximately $397,000 and the current portion of debt origination costs of approximately $10,000 as of September 30, 2024. Long-term portion of debt of approximately $301,000 is net of the long-term portion of debt discount of approximately $159,000 and the unamortized debt origination costs of approximately $3,000 as of September 30, 2024. <span id="xdx_905_eus-gaap--DebtInstrumentRedemptionDescription_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zdzkBdvHSll3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower. The Note further contains triggering events which can be remedied by the Lender requiring the Borrower to correct the triggering event, increasing the outstanding balance by applying the triggering effect, or making the Note immediately due and payable.

2500000

781250

3301250

20000

0.10

<p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_z8qR51yTaila" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Schedule of Long Term Debt <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240930_znIPEbSifguf" style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Debt schedule at September 30, 2024 (in thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: right"></td><td style="padding-bottom: 1pt"> </td> </tr> <tr id="xdx_40F_eus-gaap--LongTermDebt_iI_pn3n3_z5Qzrbi8hhlh" style="vertical-align: bottom; background-color: White"> <td style="width: 77%; text-align: left">Long-term debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">3,301</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zme2jc2Cl9lc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unamortized Original issue discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(555</td><td style="text-align: left">)</td> </tr> <tr id="xdx_40C_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zEzzylzYJd6g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14</td><td style="padding-bottom: 1pt; text-align: left">)</td> </tr> <tr id="xdx_400_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_z1sjpi9zFbp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unamortized discount and debt issuance costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,732</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_z3tDTtSH1sf1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less current portion of long-term debt, net </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,593</td><td style="padding-bottom: 1pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zfrhvPyY2899" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table>

3301000

-555000

14000

2732000

2593000

139000

226000

232000

226000

6000

750000

2551000

3000000

397000

10000

301000

159000

3000

The agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.

Note 8: Equity-Based Compensation The 2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the “2018 Equity Incentive Plan”) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. After taking into account the 44:1 reverse stock split which was effected in June 2019, initially, a maximum of 230,390 shares of common stock were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. When the plan was amended and restated, an additional 250,000 shares were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. The number of shares of the Company’s common stock available for grant and issuance under the 2018 Equity Incentive Plan is subject to an annual increase on July 1 of each calendar year, by an amount equal to two percent (2%) of the then outstanding shares of the Company’s common stock (the “2018 Plan Evergreen Provision”). On August 3, 2020, and July 1, 2021, 2022, 2023 and 2024, the number of shares of the Company’s common stock available for grant and issuance under the 2018 Equity Incentive Plan increased by 685,012 shares, 956,660 shares, 960,976 shares, 968,389 and 1,142,733 shares, respectively. As a result of the 2018 Plan Evergreen Provisions, a maximum of 5,167,160 shares of common stock is reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan as of September 30, 2024. Unless sooner terminated, the 2018 Equity Incentive Plan will continue in effect for a period of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_znPFYVH4i0Sa">10 years from its effective date. During the fiscal year ended December 31, 2018, the Board of Directors issued <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zWJLKt2DDjY2">1,189,284 options to each employee, the officers and directors at the exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zCcvL9Kb4Xnb">9.68 expiring in <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zGI9O7TGMhKe">10 years (27,028 options post reverse split). During the fiscal year ending December 31, 2019, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zeW3j5Ztk5Cj">1,727,756 options were issued to each of these officers with an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zcUoNv9gWtJ8">9.68 for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20190101__20191231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zPXJcKkMOhde">ten years with a vesting period of one year (39,266 options post reverse split). During the fiscal year ending December 31, 2020, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zmeg4dVDRNm3">1,025,000 options were issued to each of these officers and directors with an exercise price range of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zTVwL4ez8rTl">2.77 to $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z713DIxSEuT3">3.07 for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z5uk8Bere3nb">ten years with a vesting period of one year. During the fiscal year ending December 31, 2021, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zsCDxuA8GMLg">613,512 options were issued to officers, directors and consultants with an exercise price range of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_z4RfXftsVTMi">1.11 to $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxTnbndBT9Gj">1.71 for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKybHGnE7cKh">ten years with a vesting period of one year. During the fiscal year ending December 31, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zzlmhdaSrfYh">850,000 options were issued to officers, directors and consultants with an exercise price range of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKAhZBMvT4m4">0.31 to $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zSdfv7msygx6">0.71 for a period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zA0GtgA6Paga">ten years with a vesting period of one year. During the fiscal year ending December 31, 2023, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zbza9FnqKFl9">400,000 options were issued to officers with an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zTLR2sRmaCzc">0.47 for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zIvzsvbAwMue">ten years with a vesting period of one year. During the nine months ended September 30, 2024 there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20240101__20240930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zY288SslhGRk">no options issued. The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. During the nine months ended September 30, 2024, and 2023, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20230101__20230930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxe4UkvTeVB1">no options granted. Stock options activity during the three months ended September 30, 2024, was as follows: <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-KMP_zh7fODkBMfI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Stock option activity for employees: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuygrXnp4Ida" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">2,407,775</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO2ZdxITPyP5" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price beginning of year">2.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcXQXValgqj" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contracted term (years) outstanding">8.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zz3foepys7d7" style="font-family: Times New Roman, Times, Serif" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu9kAZyouNEd" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl96br6iGeB1" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrXBGXX3TFUd" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0udrqff63F2" style="text-align: right" title="Number of options forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9yFTXN7DEIh" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zLpEhzxE72P6" style="text-align: right" title="Aggregate intrinsic value forfeited">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHatSItNIaQg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQkS88vC8Ygk" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVl7uueFUn41" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zODDLWoqw4gd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending of year">2,407,680</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8runtCpDFo5" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price ending of year">2.44</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJfh0W3B2wtb" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contracted term (years) outstanding">8.70</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z07Hb7o3h5Fe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7zznmtekTr3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options vested and expected to vest">2,407,680</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8WAVUDni8sf" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price vested and expected to vest">2.44</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ztCsJt5dYN1i" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contracted term (years) vested and expected to vest">8.70</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaxkulXn0NE6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ze42OFv8xfil" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">2,341,014</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zF200Z2HV623" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price exercisable">1.66</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqS9UjHfpyq1" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contracted term (years) exercisable">7.17</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrCQrKbgDk49" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_891_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SONSATTB-QOTKSOK_zQj05qtEmQE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhDiccCtrRL9" style="width: 12%; text-align: right" title="Number of options unvested, beginning of year">166,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z1SSTLGDH6g2" style="width: 12%; text-align: right" title="Weighted average exercise price unvested, beginning of year">4.11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zU34sdnESCAk" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">18.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjJ8nJQKbSSa" style="width: 12%; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zdd2qI2xNIN3" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYxpUL1WeBSf" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zishhmNstPfh" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVKK4l7opjji" style="text-align: right" title="Number of options expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFnFZ2aAKAa" style="text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zz1zRKerhWBe" style="text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC9FXacjizv2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options vested">(99,905</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0SgBWu9JLTl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price vested">0.47</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKkpcXQqpjik" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">7.17</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQllvYF4HAFl" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value vested">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRhNOD8HJ6Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options unvested, ending of year">66,666</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7uc1Uc9Ge8e" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">9.61</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z1iIMq08n6o" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, end of year">36.22</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh2TMAdp1Xrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value end of year">—</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-DNQVA_zuXh3tppq76j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Stock option activity for non-employees: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0U3UKjpUz39" style="width: 12%; text-align: right" title="Number of options outstanding beginning of year">885,055</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeqd60RGFK7g" style="width: 12%; text-align: right" title="Weighted average exercise price beginning of year">2.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBw4kv2npTG4" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5ko2QuFtq76" style="width: 12%; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHYRLqpALTPh" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCY4UJjwqUe" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPLeK2bxONG4" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zY1N6JvQnoab" style="text-align: right" title="Number of options forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYN1qSupB3kc" style="text-align: right" title="Weighted average exercise price forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhZJT1r8rBa7" style="text-align: right" title="Aggregate intrinsic value forfeited">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhFI69MtvTl3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zG9APU7NjgA5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zblaKZwgrRa2" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsFLZOszfMdc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding ending of year">884,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zW1Mf2oUBhOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price ending of year">1.88</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE4FwmMF8uVl" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zt9neIxA5mv1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2uhtCNvWWp9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options vested and expected to vest">884,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpGGw3EWvvfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price vested and expected to vest">1.88</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoZz5DUUUis3" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), vested and expected to vest">9.23</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zANKqWtRnen2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zupy17xFdIMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">729,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ziV8aXVCzIH9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price exercisable">1.87</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYuMGrK25Xpi" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), exercisable">10.06</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZXUUzFx09Ed" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_893_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SONSATTB-BWM_z7TXuu6oUU0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGxrCWpWD9U5" style="width: 12%; text-align: right" title="Number of options unvested, beginning of year">155,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoYlrtwe0Igi" style="width: 12%; text-align: right" title="Weighted average exercise price unvested, beginning of year">3.42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoVEMBURlRDj" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">11.30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTOfao3rN8Lh" style="width: 12%; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZW30cPwV71a" style="text-align: right" title="Number of Options, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVtYE9bDoF4" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zT40OTIgMmb7" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0n4X6iePLti" style="text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJHFEKxexeO7" style="text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPgAzf1iRL0j" style="text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYIPol713VB9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">95</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3hsUXl5ZnQ3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price vested">0.46</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zP2TG4HyZL8i" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">10.18</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zb77s7RivGwk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value vested">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE2w3bbv2uFl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">155,001</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTEhDr3bwdn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">3.42</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFNMtBCQVWk" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested end of year">11.31</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZzXpjSAdEj1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value end of year">—</td><td style="text-align: left"> </td></tr> </table> Stock-based compensation expense was approximately $80,000 and $50,000 for the three months ended September 30, 2024, and 2023, resulting in an increase in general and administrative expenses, respectively. Employee stock option activity during the nine months ended September 30, 2024, was as follows: Stock option activity for employees: <div id="xdx_C06_gL3SOSBCSOASA-KMP_zFYpVLRmIcz5"> <table cellpadding="0" cellspacing="0" id="xdx_30B_134_zbpFI8KrQIwe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3mZQ0hz3kc5" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">2,408,438</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zj7mojE8uG9d" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price beginning of year">2.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNt7l5YeJQld" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrujt1jTrse8" style="font-family: Times New Roman, Times, Serif" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVNd21HtRNWb" style="text-align: right" title="Number of options, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zc6si8ZgYVu9" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zDAbiGFuz4O5" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_znvEaD6oAsV6" style="text-align: right" title="Number of options, forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZE96g5Bk5cl" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRTmOyeE2ST2" style="text-align: right" title="Aggregate intrinsic value forfeited">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_znm45sFwYaRf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired">(758</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxXSVL98Iff7" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZMlB5MjCmRc" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zAJY6Savrjrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending of year">2,407,680</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z07tKLSuhCBk" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price end of year">2.44</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqS7MM5fPK0d" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.70</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zLuYjKJ5Vjt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zAl5RkE6hM6j" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, vested and expected to vest">2,407,680</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0JiTueElZQg" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price vested and expected to vest">2.44</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXsTs2Q0A8Rh" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested and expected to vest">8.70</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhh8rObwuCe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0mkc9I2sbBg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">2,341,014</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zpkETwGWJmS1" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price exercisable">1.66</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHOEH3B5bZBg" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) exercisable">7.17</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9JylzRvMQ2f" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="text-align: left"> </td></tr> </table> </div> Unvested stock option activity for employees: <div id="xdx_C06_gL3SONSATTB-QOTKSOK_zZpy4ve80s04"> <table cellpadding="0" cellspacing="0" id="xdx_308_134_zAZ64rbchUKi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zd2XPV5bANpl" style="width: 12%; text-align: right" title="Number of options unvested, beginning of year">366,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zP0oR0ylHTAh" style="width: 12%; text-align: right" title="Weighted average exercise price unvested, beginning of year">2.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxRU6OeVsXn1" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">12.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zpJ9NUBChQVc" style="width: 12%; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZZAVtMGlvuj" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zpdnJhStCj01" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zadY1A19nMBj" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7NIaS3Gpxi8" style="text-align: right" title="Number of options expired">(758</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zciahxR1Vuja" style="text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOz2vG6r2k3h" style="text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC9uFBMRnQ54" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options vested">(299,242</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zph9jwQXPnPc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price vested">0.47</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6bKLXTbGCK8" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">7.17</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zH8pmzH6b1Bk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value vested">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwI9tqB53735" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options unvested ending of year">66,666</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIgxLKRFHag7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">9.61</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoo7YrYmoUA3" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, end of year">36.22</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zG5S4i0a4eKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value end of year">—</td><td style="text-align: left"> </td></tr> </table> </div> Stock option activity for non-employees: <div id="xdx_C04_gL3SOSBCSOASA-DNQVA_z9pVz8jZzuFk"> <table cellpadding="0" cellspacing="0" id="xdx_306_134_z5EIUSL00SQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z479kXVTXldl" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">885,055</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFGtcb6Yb31d" style="width: 12%; text-align: right" title="Weighted average exercise price beginning of year">2.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUM6S2ENJnXc" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdJzxUiLWzol" style="width: 12%; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdWfRM6ASn0g" style="text-align: right" title="Number of options, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTzqpGsFYs25" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5swWj6Sj53g" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUy3C76cdUR1" style="text-align: right" title="Number of options, forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvvfvIkUj34" style="text-align: right" title="Weighted average exercise price forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zs0BxkiALnv8" style="text-align: right" title="Aggregate intrinsic value forfeited">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSkbYtA3q9K4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zx1Nco67Kea8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zk1eWCJq6cil" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfkL1FWRzFQ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending of year">884,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGgYuA2Ehw6i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price end of year">1.88</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zenO6rEA3Xdc" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTfOjBqtMLa5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhpSaXqGf1Qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, vested and expected to vest">884,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9Je5ZpmUgA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price vested and expected to vest">1.88</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze7ypxgb3eNg" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested and expected to vest">9.23</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4uQ82kVdILj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwEy0i8hh4Re" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">729,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zirZhj9gSqzg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price exercisable">1.87</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgwc1guJkza6" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) exercisable">10.06</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYcexDlS4ucb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="text-align: left"> </td></tr> </table> </div> Unvested stock option activity for non-employees: <div id="xdx_C01_gL3SONSATTB-BWM_zOhQk7WcFAvi"> <table cellpadding="0" cellspacing="0" id="xdx_305_134_zi3j29Bqb4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1CJvb8Som0j" style="width: 12%; text-align: right" title="Number of options unvested, beginning of year">335,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8W0lZOFRmc5" style="width: 12%; text-align: right" title="Weighted average exercise price unvested, beginning of year">1.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z48WcXtEjKjf" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">10.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7eUam0reGE" style="width: 12%; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zW6gl0kma3rf" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zavPASo42pSf" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYscNKzJAkFi" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0VsRqHzGE6h" style="text-align: right" title="Number of options expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9zbo7bLQ0qk" style="text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRPKi0q3WOH8" style="text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRspcm2i8fKc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options vested">(179,905</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4m0eBxVeQP6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price vested">0.46</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGol0V6JTvh5" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">10.18</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAURzm4tAzl8" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value vested">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zF53KCAwbBQ" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options unvested ending of year">155,001</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoDouYS0XFJ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">3.42</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjmCB7kb93na" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, end of year">11.31</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWLvnJbijvf9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value end of year">—</td><td style="text-align: left"> </td></tr> </table> </div> Stock-based compensation expense was approximately $490,000 and $182,000 for the nine months ended September 30, 2024, and 2023, respectively. As part of the Company’s cash conservation strategy, the Company issued common stock as a substitute for cash salaries to certain executives. For the three and nine months ended September 30, 2024, stock issued as payroll totaled $250,000, which is included in the overall equity-based compensation expense. There was no stock issued as payroll for the three and nine months ended September 30, 2023. On September 30, 2024, and 2023, respectively, there was approximately $53,400 and $35,000 of unrecognized equity-based compensation cost related to options granted under the Equity Incentive Plan.

44:1 reverse stock split

230390

250000

685012

956660

960976

968389

1142733

5167160

P10Y

1189284

9.68

P10Y

(27,028 options post reverse split)

1727756

9.68

P10Y

one year (39,266 options post reverse split).

1025000

2.77

3.07

P10Y

613512

1.11

1.71

P10Y

850000

0.31

0.71

P10Y

400000

0.47

P10Y

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-KMP_zh7fODkBMfI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Stock option activity for employees: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuygrXnp4Ida" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">2,407,775</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO2ZdxITPyP5" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price beginning of year">2.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcXQXValgqj" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contracted term (years) outstanding">8.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zz3foepys7d7" style="font-family: Times New Roman, Times, Serif" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu9kAZyouNEd" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl96br6iGeB1" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrXBGXX3TFUd" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0udrqff63F2" style="text-align: right" title="Number of options forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9yFTXN7DEIh" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zLpEhzxE72P6" style="text-align: right" title="Aggregate intrinsic value forfeited">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHatSItNIaQg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQkS88vC8Ygk" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVl7uueFUn41" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zODDLWoqw4gd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending of year">2,407,680</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8runtCpDFo5" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price ending of year">2.44</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJfh0W3B2wtb" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contracted term (years) outstanding">8.70</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z07Hb7o3h5Fe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7zznmtekTr3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options vested and expected to vest">2,407,680</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8WAVUDni8sf" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price vested and expected to vest">2.44</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ztCsJt5dYN1i" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contracted term (years) vested and expected to vest">8.70</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaxkulXn0NE6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ze42OFv8xfil" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">2,341,014</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zF200Z2HV623" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price exercisable">1.66</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqS9UjHfpyq1" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contracted term (years) exercisable">7.17</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrCQrKbgDk49" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_30B_134_zbpFI8KrQIwe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3mZQ0hz3kc5" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">2,408,438</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zj7mojE8uG9d" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price beginning of year">2.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNt7l5YeJQld" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrujt1jTrse8" style="font-family: Times New Roman, Times, Serif" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVNd21HtRNWb" style="text-align: right" title="Number of options, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zc6si8ZgYVu9" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zDAbiGFuz4O5" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_znvEaD6oAsV6" style="text-align: right" title="Number of options, forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZE96g5Bk5cl" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRTmOyeE2ST2" style="text-align: right" title="Aggregate intrinsic value forfeited">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_znm45sFwYaRf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired">(758</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxXSVL98Iff7" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZMlB5MjCmRc" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zAJY6Savrjrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending of year">2,407,680</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z07tKLSuhCBk" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price end of year">2.44</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqS7MM5fPK0d" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.70</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zLuYjKJ5Vjt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zAl5RkE6hM6j" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, vested and expected to vest">2,407,680</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0JiTueElZQg" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price vested and expected to vest">2.44</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXsTs2Q0A8Rh" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested and expected to vest">8.70</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhh8rObwuCe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0mkc9I2sbBg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">2,341,014</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zpkETwGWJmS1" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price exercisable">1.66</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHOEH3B5bZBg" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) exercisable">7.17</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9JylzRvMQ2f" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="text-align: left"> </td></tr> </table>

2407775

2.50

P8Y8M12D

2407680

2.44

P8Y8M12D

2407680

2.44

P8Y8M12D

2341014

1.66

P7Y2M1D

<p id="xdx_891_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SONSATTB-QOTKSOK_zQj05qtEmQE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhDiccCtrRL9" style="width: 12%; text-align: right" title="Number of options unvested, beginning of year">166,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z1SSTLGDH6g2" style="width: 12%; text-align: right" title="Weighted average exercise price unvested, beginning of year">4.11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zU34sdnESCAk" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">18.87</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjJ8nJQKbSSa" style="width: 12%; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zdd2qI2xNIN3" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYxpUL1WeBSf" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zishhmNstPfh" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVKK4l7opjji" style="text-align: right" title="Number of options expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFnFZ2aAKAa" style="text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zz1zRKerhWBe" style="text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC9FXacjizv2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options vested">(99,905</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0SgBWu9JLTl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price vested">0.47</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKkpcXQqpjik" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">7.17</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zQllvYF4HAFl" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value vested">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRhNOD8HJ6Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options unvested, ending of year">66,666</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7uc1Uc9Ge8e" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">9.61</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z1iIMq08n6o" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, end of year">36.22</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh2TMAdp1Xrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value end of year">—</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_308_134_zAZ64rbchUKi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zd2XPV5bANpl" style="width: 12%; text-align: right" title="Number of options unvested, beginning of year">366,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zP0oR0ylHTAh" style="width: 12%; text-align: right" title="Weighted average exercise price unvested, beginning of year">2.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxRU6OeVsXn1" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">12.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zpJ9NUBChQVc" style="width: 12%; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZZAVtMGlvuj" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zpdnJhStCj01" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zadY1A19nMBj" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7NIaS3Gpxi8" style="text-align: right" title="Number of options expired">(758</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zciahxR1Vuja" style="text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOz2vG6r2k3h" style="text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC9uFBMRnQ54" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options vested">(299,242</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zph9jwQXPnPc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price vested">0.47</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6bKLXTbGCK8" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">7.17</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zH8pmzH6b1Bk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value vested">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwI9tqB53735" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options unvested ending of year">66,666</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIgxLKRFHag7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">9.61</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoo7YrYmoUA3" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, end of year">36.22</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zG5S4i0a4eKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value end of year">—</td><td style="text-align: left"> </td></tr> </table>

166666

4.11

P18Y10M13D

99905

0.47

P7Y2M1D

66666

9.61

P36Y2M19D

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-DNQVA_zuXh3tppq76j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Stock option activity for non-employees: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0U3UKjpUz39" style="width: 12%; text-align: right" title="Number of options outstanding beginning of year">885,055</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeqd60RGFK7g" style="width: 12%; text-align: right" title="Weighted average exercise price beginning of year">2.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBw4kv2npTG4" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5ko2QuFtq76" style="width: 12%; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHYRLqpALTPh" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCY4UJjwqUe" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPLeK2bxONG4" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zY1N6JvQnoab" style="text-align: right" title="Number of options forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYN1qSupB3kc" style="text-align: right" title="Weighted average exercise price forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhZJT1r8rBa7" style="text-align: right" title="Aggregate intrinsic value forfeited">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhFI69MtvTl3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zG9APU7NjgA5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zblaKZwgrRa2" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsFLZOszfMdc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding ending of year">884,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zW1Mf2oUBhOf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price ending of year">1.88</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE4FwmMF8uVl" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zt9neIxA5mv1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2uhtCNvWWp9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options vested and expected to vest">884,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpGGw3EWvvfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price vested and expected to vest">1.88</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoZz5DUUUis3" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), vested and expected to vest">9.23</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zANKqWtRnen2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zupy17xFdIMj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">729,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ziV8aXVCzIH9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price exercisable">1.87</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYuMGrK25Xpi" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), exercisable">10.06</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZXUUzFx09Ed" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_306_134_z5EIUSL00SQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z479kXVTXldl" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">885,055</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFGtcb6Yb31d" style="width: 12%; text-align: right" title="Weighted average exercise price beginning of year">2.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUM6S2ENJnXc" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdJzxUiLWzol" style="width: 12%; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdWfRM6ASn0g" style="text-align: right" title="Number of options, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTzqpGsFYs25" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5swWj6Sj53g" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUy3C76cdUR1" style="text-align: right" title="Number of options, forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvvfvIkUj34" style="text-align: right" title="Weighted average exercise price forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zs0BxkiALnv8" style="text-align: right" title="Aggregate intrinsic value forfeited">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSkbYtA3q9K4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zx1Nco67Kea8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zk1eWCJq6cil" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfkL1FWRzFQ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending of year">884,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGgYuA2Ehw6i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price end of year">1.88</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zenO6rEA3Xdc" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTfOjBqtMLa5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhpSaXqGf1Qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, vested and expected to vest">884,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9Je5ZpmUgA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price vested and expected to vest">1.88</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze7ypxgb3eNg" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested and expected to vest">9.23</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4uQ82kVdILj" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwEy0i8hh4Re" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">729,960</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zirZhj9gSqzg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price exercisable">1.87</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgwc1guJkza6" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) exercisable">10.06</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYcexDlS4ucb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="text-align: left"> </td></tr> </table>

885055

2.02

P9Y2M23D

884960

1.88

P9Y2M23D

884960

1.88

P9Y2M23D

729960

1.87

P10Y21D

<p id="xdx_893_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SONSATTB-BWM_z7TXuu6oUU0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGxrCWpWD9U5" style="width: 12%; text-align: right" title="Number of options unvested, beginning of year">155,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoYlrtwe0Igi" style="width: 12%; text-align: right" title="Weighted average exercise price unvested, beginning of year">3.42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoVEMBURlRDj" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">11.30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTOfao3rN8Lh" style="width: 12%; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZW30cPwV71a" style="text-align: right" title="Number of Options, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVtYE9bDoF4" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zT40OTIgMmb7" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0n4X6iePLti" style="text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJHFEKxexeO7" style="text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPgAzf1iRL0j" style="text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYIPol713VB9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">95</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3hsUXl5ZnQ3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price vested">0.46</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zP2TG4HyZL8i" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">10.18</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zb77s7RivGwk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value vested">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE2w3bbv2uFl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">155,001</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTEhDr3bwdn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">3.42</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFNMtBCQVWk" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested end of year">11.31</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZzXpjSAdEj1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value end of year">—</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_305_134_zi3j29Bqb4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1CJvb8Som0j" style="width: 12%; text-align: right" title="Number of options unvested, beginning of year">335,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8W0lZOFRmc5" style="width: 12%; text-align: right" title="Weighted average exercise price unvested, beginning of year">1.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z48WcXtEjKjf" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">10.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7eUam0reGE" style="width: 12%; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zW6gl0kma3rf" style="text-align: right" title="Number of options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zavPASo42pSf" style="text-align: right" title="Weighted average exercise price granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYscNKzJAkFi" style="text-align: right" title="Aggregate intrinsic value granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0VsRqHzGE6h" style="text-align: right" title="Number of options expired">(95</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9zbo7bLQ0qk" style="text-align: right" title="Weighted average exercise price expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRPKi0q3WOH8" style="text-align: right" title="Aggregate intrinsic value expired">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRspcm2i8fKc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options vested">(179,905</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4m0eBxVeQP6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price vested">0.46</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGol0V6JTvh5" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">10.18</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAURzm4tAzl8" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value vested">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested September 30, 2024</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zF53KCAwbBQ" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options unvested ending of year">155,001</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoDouYS0XFJ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">3.42</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjmCB7kb93na" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, end of year">11.31</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWLvnJbijvf9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value end of year">—</td><td style="text-align: left"> </td></tr> </table>

155001

3.42

P11Y3M18D

0.46

P10Y2M4D

155001

3.42

P11Y3M21D

80000

50000

2408438

2.50

P8Y8M12D

758

2407680

2.44

P8Y8M12D

2407680

2.44

P8Y8M12D

2341014

1.66

P7Y2M1D

366666

2.13

P12Y5M8D

758

299242

0.47

P7Y2M1D

66666

9.61

P36Y2M19D

885055

2.02

P9Y2M23D

884960

1.88

P9Y2M23D

884960

1.88

P9Y2M23D

729960

1.87

P10Y21D

335001

1.83

P10Y8M12D

179905

0.46

P10Y2M4D

155001

3.42

P11Y3M21D

490000

182000

250000

53400

35000

Note 9: Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 shares of $0.01 par value preferred stock with such designations, rights and preferences as may be determined by the Board. Of our authorized preferred stock, 4,000,000 shares have been designated as Series A Junior Participating Preferred Stock and 10,000 shares have been designated as Series B Convertible Preferred Stock. Series A Junior Participating Preferred Stock On May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series A Junior Participating Preferred Stock to <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zLV1Pods1TFj" title="Preferred stock, shares authorized">4,000,000 from <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_z23cz10nnsV9" title="Preferred stock, shares authorized">250,000 shares. As of September 30, 2024, there were no Series A Junior Participating Preferred Stock outstanding. Series B Convertible Preferred Stock The Company has designated 10,000 shares of its preferred stock as Series B Convertible Preferred Stock (the “Preferred Stock”). Each share of Preferred Stock has a par value of $0.01 per share and a stated value equal to $<span id="xdx_906_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zbdxAwYB14q4" title="Preferred stock, stated value">1,000 (the “Stated Value”). The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of the shares of Preferred Stock. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option of the Corporation, into that number of shares of common stock (subject in each case to the limitations determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $0.20, subject to adjustment herein (the “Conversion Price”). Pursuant to a registration statement relating to a rights offering (the “Rights Offering”) declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into common stock at an assumed conversion price of $8.80) and 114 warrants with an assumed exercise price of $8.80. The redeemable warrants are exercisable for five years after the date of issuance. The net proceeds realized from the rights offering were approximately $4,700,000. As of September 30, 2024, 689 shares of Series B Convertible Preferred Stock had expired, and none were converted prior to expiration. (b) Common Stock and Equity Finances The Company has authorized shares of 350,000,000 with specific limitations and restrictions on the usage of 8,000,000 of the 350,000,000 authorized shares. As of September 30, 2024, and December 31, 2023, there were 58,668,647 and 49,102,484 shares of common stock issued and outstanding, respectively. Employee Stock Purchase Plan (Not equity compensation) On July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $500,000 worth of shares at the market price (including subsequent plans, the “Employee Stock Purchase Plan”). Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved the Company’s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7, 2020 plan. The latest plan was approved by the Board on October 21, 2024 and expires in December 2024. During the three months ended September 30, 2024, the Company did not issue any shares of its common stock as part of the employee stock purchase plan. During the nine months ended September 30, 2024, the Company issued a total of 335,603 shares of its common stock at a price ranging from $0.33 to $0.41 for total proceeds of approximately $120,000 as part of the employee stock purchase plan. During the three months ended September 30, 2023, the Company issued a total of 62,841 shares of its common stock at a price ranging from $0.44 to $0.67 for total proceeds of approximately $35,500 as part of the employee stock purchase plan. During the nine months ended September 30, 2023, the Company issued a total of 385,424 shares of its common stock at a price ranging from $0.31 to $0.67 for total proceeds of approximately $135,000 as part of the employee stock purchase plan. Rights Plan On May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer & Trust Company as Rights Agent (the “Rights Plan”). Warrants (Rights offering) On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 shares of common stock; (ii) pre-funded warrants exercisable for 7,148,310 shares of common stock (the “Pre-funded Warrants”), and (iii) warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zk06vIxeMAvj">8,888,860 shares of common stock (the “Warrants”). In conjunction with the Offering, we issued a Representative’s Warrant to purchase up to an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zpn7ey1dppSj">266,665 shares of common stock (the “Representative’s Warrant”). The shares of common stock and Warrants were sold at a combined Offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zxpcFYlkmU31">0.90, less underwriting discounts and commissions. Each Warrant sold with the shares of common stock represents the right to purchase one share of common stock at an exercise price of $0.99 per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $0.899, less underwriting discounts and commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of common stock in the Offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than <span id="xdx_909_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zlUlJKuT6jy1" title="Percentage of outstanding stock">4.99% of the Company’s outstanding common stock immediately following the consummation of the Offering, in lieu of shares of common stock. Each Pre-Funded Warrant represents the right to purchase one share of common stock at an exercise price of $0.001 per share. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1, relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately $7,200,000. During the year ended December 31, 2020, 1,870,000 of the Pre-funded Warrants were exercised and 8,873,960 Warrants were exercised. In addition, on March 25, 2020, the Representative’s Warrant was amended to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020, and an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLqkg4B09CUi">266,665 shares were issued upon exercise of this warrant for gross proceeds of approximately $264,000 and a $46,000 expense for the warrant modification. During the three months ended September 30, 2024, there were no warrants exercised and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240701__20240930__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_zHNu2Pq7YRr7">15,000 warrants expired unexercised. During the nine months ended September 30, 2024, 205,000 warrants were exercised, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20240930__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_zoUWDRKMyD7l">5,830,028 warrants expired unexercised. As of September 30, 2024 there were no warrants outstanding and December 31, 2023 there were 152,160 post-split warrants outstanding, respectively. Equity Distribution Agreement On April 19, 2023, the Company entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMEtwbeO6O05">8,500 000 through Maxim, as agent (the “Offering”). Sales under the EDA were registered under the S-3 Shelf Registration Statement. Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of <span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zGKFVuUhU4M1">3.0% of the gross sales price of shares sold under the EDA. During the year ended December 31, 2023, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zOJlSDZcgXu4">598,114 shares under the EDA for total gross proceeds of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3ggv6RmBjze">344,000, which includes a <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zhWfTBAG9ojb">3.0% fee to Maxim of $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMIXKv7gdpsi">10,326. For the three months ended September 30, 2024, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zCHh2hYi6Ji5">10,975 shares under the EDA for total gross proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zr2xUwumO2Yd">4,110, which includes a <span id="xdx_901_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zhodRipzm8lg">3.0% fee to Maxim of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zFuh0L88Yfz9">123. For the nine months ended September 30, 2024, the Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z8NOpmnjpGOa">1,305,653 shares under the EDA for total gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z90Up4udVZB9">630,204 which includes a <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z61pkh309uQi">3.0% fee to Maxim of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zy8xvhzKMFqd">18,906. Unsecured Promissory Note On February 16, 2024, the Company (“Borrower”) entered into a Note Purchase Agreement with Streeterville Capital LLC (“Streeterville” or the “Lender”). Under the terms of the agreement, Streeterville paid the Company $2,500,000 in exchange for an unsecured promissory Note with an Original Issue Discount of $781,250. The Company will pay $3,301,250 consisting of the principal amount of the Note, together with the original issue discount and $20,000 of lender transaction fees, no later than February 16, 2026. The stated interest rate of the note is 10%. There was no debt at December 31, 2023. In 2024, the Company made three redemption payments in stock rather than cash, helping to preserve AIM’s funds. AIM is in discussion to possibly pay future redemptions in stock. Equity Purchase Agreement On March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement with Atlas Sciences, LLC (“Atlas”), pursuant to which Atlas committed to purchase up to $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240328__20240328__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndRegistrationRightsAgreementMember_z6Qmmo76xiK6">15,000,000 of common stock of the Company for a period of 24 months from the date of the purchase agreement. No assurance can be given as to the actual amount that will be raised pursuant to the purchase agreement. Under the terms of the purchase agreement, the Company, at its sole discretion, shall have the right to issue Put shares to the Investor at <span id="xdx_905_ecustom--MarketPricePercentage_iI_pid_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zJw0Tzn4ICVe" title="Market price, percentage">95% of the Market Price of the shares on the day of trade. Sales under the purchase agreement are limited to a daily maximum of the lessor of: $<span id="xdx_904_ecustom--TradingDailyMaximumLessorAmount_c20240328__20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zQAeblUWAl9c" title="Trading maximum lessor amount">500,000, the Median Daily Trading volume, and a beneficial ownership limitation of <span id="xdx_903_ecustom--BeneficialOwnershipPercentage_iI_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0AnndGrwoUb" title="Beneficial ownership percentage">4.99% and a maximum of <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240328__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z8iLdsFcRGO7">19.99% of the outstanding shares at the time of the purchase agreement. In April 2024, the Company filed a registration statement with the SEC on Form S-1 registering a total of 9,975,000 shares for resale pursuant to the Atlas Agreements, consisting of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpx0vsEx6u2j">9,636,400 shares that can be sold by the Company to Atlas and <span id="xdx_900_ecustom--StockIssuedDuringPeriodValueCommitmentShares_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zTv35dBCD9x6" title="Commitment shares issued">338,600 shares that were issued to Atlas as Commitment Shares. The registration statement was declared effective on May 1, 2024. There were no shares issued for the three months ended September 30, 2024. As of September 30, 2024, a total of 759,685 shares have been issued pursuant to the purchase agreement for a total of approximately $128,000. Securities Purchase Agreement On May 31, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) to complete an offering (the “Transactions”) with a single accredited investor (the “Purchaser”), pursuant to which, on June 3, 2024, the Company issued to the Purchaser, (i) in a registered direct offering, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zvsNQakMz1Dk">5,640,958 shares of the Company’s common stock (the “Shares”), par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjHrPc0hk8Df">0.001 per share (“common stock”) and (ii) in a concurrent private placement, the Company issued to the Purchaser Class A common warrants to purchase an aggregate of up to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z0WsGfhJuftl">5,640,958 shares of its common stock (the “A Warrants”) at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zvOT7C0I7JFf">0.363 per share and Class B common warrants to purchase an aggregate of up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonWarrantMember_zEJtUG87iYxd">5,640,958 shares of its common stock (the “B “Warrants” and, along with the A Warrants, the “Common Warrants”) at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonWarrantMember_zwuJnVqAau9e">0.363 per share. The A Warrants and B Warrants are not exercisable for six months after the issuance date and expire, respectively, 24 months and five years and six months after the issuance date. The Common Warrants and the shares of common stock issuable upon the exercise of such warrants are offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The Shares were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective on February 4, 2022 (as amended from time to time, the “Registration Statement”). Pursuant to the terms of the Purchase Agreement, subject to certain exceptions, the Company could not issue any equity securities for 60 days following the issuance date, provided that the Company was able to utilize its at-the-market offering program with the Placement Agent after 30 days. Additionally, the Company cannot enter into a variable rate transaction (other than the ATM program with the Placement Agent) for 120 days after the issuance date. In addition, the Company’s executive officers and each of the Company’s directors have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the closing of the Transactions, offer, sell, transfer or otherwise dispose of the Company’s securities, subject to certain exceptions. The exercise price of the Common Warrants, and the number of Common Warrant Shares, are subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity had been named in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants are exercisable on a “cashless” basis only if there is not a current registration statement permitting public resale. In this regard, the Company filed a registration statement to register the resale of the Common Warrant Shares providing for the resale of the Shares issued and issuable upon exercise of the Common Warrants. That registration statement was declared effective by the SEC on July 11, 2024. The Company has agreed to use commercially reasonable efforts to cause such registration statement to keep such registration statement effective at all times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof. Maxim Group LLC acted as the placement agent (the “Placement Agent”) on a “commercially reasonable best efforts” basis, in connection with the Transactions pursuant to the Placement Agency Agreement, dated May 31, 2024 (the “Placement Agency Agreement”), by and between the Company and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent was paid a cash fee of 8% of the aggregate gross proceeds paid to the Company for the securities sold in the Transactions and reimbursement of certain out-of-pocket expenses. The Company evaluated the Common Warrants under the guidance of ASC 480 – Distinguishing Liabilities from Equity and determined that they were in scope under the guidance as freestanding financial instruments but did not meet the criteria for liability classification and are classified as equity within the condensed consolidated financial statements. Proceeds allocated to such warrants totaled approximately $2.5 million. For the nine months ended September 30,2024, no Common Warrants were exercised, and all remain outstanding on September 30, 2024 related to this agreement. On September 30, 2024, the Company entered into a Securities Purchase Agreement to complete an offering with a single accredited investor. For more information see Note 15: Subsequent Events.

5000000

0.01

4000000

10000

4000000

250000

10000

0.01

1000

0.20

1000

8.80

114

8.80

4700000

689

350000000

8000000

350000000

58668647

49102484

500000

335603

0.33

0.41

120000

62841

0.44

0.67

35500

385424

0.31

0.67

135000

1740550

7148310

8888860

266665

0.90

0.99

0.899

0.0499

0.001

7200000

1870000

8873960

266665

264000

46000

15000

205000

5830028

152160

8500

0.030

598114

344000

0.030

10326

10975

4110

0.030

123

1305653

630204

0.030

18906

15000000

0.95 500000 0.0499

0.1999

9975000

9636400

338600

759685

128000

5640958

0.001

5640958

0.363

5640958

0.363

0.08

2500000

Note 10: Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0jmiCxJTYMe">14,574,557 and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z7URUNwRkmuh">2,763,020 shares for the nine months ended September 30, 2024 and 2023, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

14574557

2763020

Note 11: Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. Accounting pronouncements issued by the FASB since filing the Annual Report on Form 10-K for the year ended December 31, 2023 did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Note 12: Fair Value Fair Value The Company complies with the provisions of FASB ASC 820 “Fair Value Measurements” for its financial and non-financial assets and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. The fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items and are considered a Level 1 instrument of the fair value measurements standard. The Company also has certain warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the warrants (“June 2024 Warrants”) related to the Company’s June 2024 common stock and warrant issuance, are calculated using a Monte Carlo Simulation. The Company also had certain redeemable warrants in the Rights Offering with a cash settlement feature in the occurrence of a Fundamental Transaction. No Fundamental Transaction occurred. In March 2024, 205,000 of these warrants converted on a cashless basis and 5,830,028 expired. The Company estimated the fair value of the June 2024 Warrants using the Black-Scholes Model, which uses multiple inputs including the Company’s stock price, the exercise price of the warrant, volatility of the Company’s stock price, the risk-free interest rate and the expected term of the warrants. <p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zBwemeKBRwZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company utilized the following assumptions to estimate the fair value of the Class A Warrants: Schedule of Assumptions to Estimate the Fair Value <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zrOaFkfzA9pg" style="font-family: Times New Roman, Times, Serif" title="Underlying price per share">0.350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1SXL4V6iFL9" style="font-family: Times New Roman, Times, Serif" title="Underlying price per share">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1qnD1s4Bd41" style="font-family: Times New Roman, Times, Serif" title="Exercise price per share">0.363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zarSrwB6uK4h" style="font-family: Times New Roman, Times, Serif" title="Exercise price per share">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zymx6q6nXSRk" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">4.42</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zpfrKywBrq7f" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zENFNPAg5FVh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected holding period">5.5 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zjqHNNNAlKO1" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">110</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zcqTtdfEA5Fh" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zFqHUKwnFD42" style="font-family: Times New Roman, Times, Serif" title="Expected dividend yield">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNL2HgGONm48" style="font-family: Times New Roman, Times, Serif" title="Expected dividend yield">—</td><td style="text-align: left"> </td></tr> </table> The Company utilized the following assumptions to estimate the fair value of the Class B Warrants: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zcx7m92KfGD4" style="font-family: Times New Roman, Times, Serif" title="Underlying price per share">0.350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zAd5NYoNmiHh" style="font-family: Times New Roman, Times, Serif" title="Underlying price per share">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zACQiJxKlIN4" style="font-family: Times New Roman, Times, Serif" title="Exercise price per share">0.363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zd8inJQdFyOd" style="font-family: Times New Roman, Times, Serif" title="Exercise price per share">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zHLudfZhpro3" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">4.82</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zwIvvkt1o8E6" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zvHVzb2RivJh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected holding period">2 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zdlhhDUyP0Oe" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">89</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zfzOJghkrTjf" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zNqazrfVjdka" style="font-family: Times New Roman, Times, Serif" title="Expected dividend yield">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zm8z5p5eN9ze" style="font-family: Times New Roman, Times, Serif" title="Expected dividend yield">—</td><td style="text-align: left"> </td></tr> </table> The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-Free Interest Rate. The risk-free interest rates for the Warrants are based on U.S. Treasury constant maturities for periods commensurate with the remaining expected holding periods of the warrants.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(ii)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Holding Period. The expected holding period represents the period of time that the Warrants are expected to be outstanding until they are exercised. The Company utilizes the remaining contractual term of the Warrants at each valuation date as the expected holding period.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(iii)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Volatility. Expected stock volatility is based on daily observations of the Company’s historical stock values for a period commensurate with the remaining expected holding period on the last day of the period for which the computation is made.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(iv)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Dividend Yield. The expected dividend yield is based on the Company’s anticipated dividend payments over the remaining expected holding period. As the Company has never issued dividends, the expected dividend yield is 0% and this assumption will be continued in future calculations unless the Company changes its dividend policy.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(v)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Probability of a Fundamental Transaction. Put rights arise if a Fundamental Transaction 1) is an all cash transaction; (2) results in the Company going private; or (3) is a transaction involving a person or entity not traded on a national securities exchange. The Company believes such an occurrence is unlikely because:</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company only has one product that is FDA approved but is currently not available for commercial sales.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company will have to perform additional clinical trials for FDA approval of its flagship product.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Industry and market conditions continue to include uncertainty, adding risk to any transaction.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research & Development.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">5.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">6.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer.</td></tr></table> <p id="xdx_899_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z1oSiJHN4Lh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Potential Liability <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%; text-align: center; padding-left: 3pt">Low</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-left: 3pt">Medium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 3pt">High</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left">%</td></tr> </table> The Monte Carlo Simulation has incorporated a 5.0% probability of a Fundamental Transaction to date for the life of the securities. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt">(vi)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Timing of Announcement of a Fundamental Transaction. As the Company has no specific expectation of a Fundamental Transaction, for reasons elucidated above, the Company utilized a discrete uniform probability distribution over the Expected Holding Period to model in the potential announcement of a Fundamental Transaction occurring during the Expected Holding Period.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt">(vii)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected 100 Day Volatility at Announcement of a Fundamental Transaction. An estimate of future volatility is necessary as there is no mechanism for directly measuring future stock price movements. Daily observations of the Company’s historical stock values for the 100 days immediately prior to the Warrants’ grant dates, with a floor of 100%, were utilized as a proxy for future volatility estimates.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt">(viii)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction. The Company utilized a risk-free interest rate corresponding to the forward U.S. Treasury rate for the period equal to the time between the date forecast for the public announcement of a Fundamental Transaction and the Warrant expiration date for each simulation.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt">(ix)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Time Between Announcement and Consummation of a Fundamental Transaction. The expected time between the announcement and the consummation of a Fundamental Transaction is based on the Company’s experience with the due diligence process performed by acquirers and is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional period to reflect the delay Warrant Holders would experience in receiving the proceeds of the Put.</td></tr></table> While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the actual historical prices input for the relevant period input change. The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of September 30, 2024, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants.</td></tr></table> The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of September 30, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxI1fwhW7vZh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">67</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zo0YJhRvvtb9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">67</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYjPFy5GJxAk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2eiI3hcGQT3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znmv5wHU5Mge" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">6,287</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwKrJddrvvLh" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">6,287</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSMPJ5JARYjf" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7JCcs4ifYu8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zP7N3paE1grj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zW1g7juGpFkb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeQ27myYYqe5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVkicbnuFTJj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zY5zOnocsS28" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">7,631</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgvGWqDD5Ceg" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">7,631</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXX0M7FTZgA8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJWTJVzn7wBi" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

205000

5830028

<p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zBwemeKBRwZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company utilized the following assumptions to estimate the fair value of the Class A Warrants: Schedule of Assumptions to Estimate the Fair Value <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zrOaFkfzA9pg" style="font-family: Times New Roman, Times, Serif" title="Underlying price per share">0.350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1SXL4V6iFL9" style="font-family: Times New Roman, Times, Serif" title="Underlying price per share">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1qnD1s4Bd41" style="font-family: Times New Roman, Times, Serif" title="Exercise price per share">0.363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zarSrwB6uK4h" style="font-family: Times New Roman, Times, Serif" title="Exercise price per share">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zymx6q6nXSRk" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">4.42</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zpfrKywBrq7f" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zENFNPAg5FVh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected holding period">5.5 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zjqHNNNAlKO1" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">110</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zcqTtdfEA5Fh" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zFqHUKwnFD42" style="font-family: Times New Roman, Times, Serif" title="Expected dividend yield">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNL2HgGONm48" style="font-family: Times New Roman, Times, Serif" title="Expected dividend yield">—</td><td style="text-align: left"> </td></tr> </table> The Company utilized the following assumptions to estimate the fair value of the Class B Warrants: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zcx7m92KfGD4" style="font-family: Times New Roman, Times, Serif" title="Underlying price per share">0.350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zAd5NYoNmiHh" style="font-family: Times New Roman, Times, Serif" title="Underlying price per share">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zACQiJxKlIN4" style="font-family: Times New Roman, Times, Serif" title="Exercise price per share">0.363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zd8inJQdFyOd" style="font-family: Times New Roman, Times, Serif" title="Exercise price per share">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zHLudfZhpro3" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">4.82</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zwIvvkt1o8E6" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zvHVzb2RivJh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected holding period">2 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zdlhhDUyP0Oe" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">89</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zfzOJghkrTjf" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zNqazrfVjdka" style="font-family: Times New Roman, Times, Serif" title="Expected dividend yield">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zm8z5p5eN9ze" style="font-family: Times New Roman, Times, Serif" title="Expected dividend yield">—</td><td style="text-align: left"> </td></tr> </table>

0.350

0.363

4.42

P5Y6M

1.10

0.350

0.363

4.82

P2Y

0.89

<p id="xdx_899_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z1oSiJHN4Lh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Potential Liability <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%; text-align: center; padding-left: 3pt">Low</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-left: 3pt">Medium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 3pt">High</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left">%</td></tr> </table> 0.005 0.010 0.050 0.050

The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of September 30, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxI1fwhW7vZh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">67</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zo0YJhRvvtb9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">67</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYjPFy5GJxAk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2eiI3hcGQT3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znmv5wHU5Mge" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">6,287</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwKrJddrvvLh" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">6,287</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSMPJ5JARYjf" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7JCcs4ifYu8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zP7N3paE1grj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zW1g7juGpFkb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeQ27myYYqe5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVkicbnuFTJj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zY5zOnocsS28" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">7,631</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgvGWqDD5Ceg" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">7,631</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXX0M7FTZgA8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJWTJVzn7wBi" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

67000

6287000

4805000

7631000

Note 13: Leases The Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 to 5 years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $1,000 to $17,000. Certain leases include additional renewal options ranging from 1 to 5 years. AIM has classified all of its leases as operating leases. At September 30, 2024 and December 31, 2023, the balance of the right of use assets was $653,000 and $697,000, respectively, and the corresponding operating lease liability balance was $669,000 and $718,000, respectively. Right of use assets are recorded net of accumulated amortization of $404,000 and $363,000 as of September 30, 2024 and December 31, 2023, respectively. AIM recognized rent expense associated with these leases are follows: Schedule of AIM Recognized Rent Expense Associated with Operating Lease <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20240101__20240930_zTI3OTTC3hs3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td> </td><td> </td> <td colspan="2" id="xdx_494_20230101__20230930_zDEerU0nJsUd" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_z4nmxel6skb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease costs:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseCost_pn3n3_maLCzBan_zsdk9W45uZG6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">226</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">214</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzBan_zvageJeGouK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Short-term and variable lease costs</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">205</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">253</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzBan_zZ6TvucId2ae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total lease costs</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Classification of lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3pRw35uNfzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Research & development</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0Zk0RR1SeEd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">General and administrative</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_zpv8JbELhHWh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total lease costs</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467</td><td style="text-align: left"> </td></tr> </table> The Company’s leases have remaining lease terms between 6 and 35 months. At September 30, 2024, the weighted-average remaining term was 32 months. At December 31, 2023, the weighted-average remaining term was 41 months. The Company’s weighted average incremental borrowing rate for its leases was 10.2% at September 30, 2024 and 10% at December 31, 2023. Future minimum payments as of September 30, 2024, are as follows: Schedule of Operating Lease Future Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td> </td> <td colspan="2" id="xdx_499_20240930_zfOCBbh5b624" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zwSmoTAsuoMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">78</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zo2ACskIj2Qi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Remainder year</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">78</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zG5gFMTW9ikh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zS98VF0BHrU2" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year one</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zO1zmA5VOGjd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zdqBlEQ5CUp8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zFVVWdKsf0g1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zNiQ2sSMMXGg" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_zohhKwodUyE1" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_zjlMJs4DZV7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zl1WmhMJO9tl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(88</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zCm8nqEVfErg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">669</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P1Y

P5Y

1000

17000

P1Y

P5Y

653000

697000

669000

718000

404000 363000

AIM recognized rent expense associated with these leases are follows: Schedule of AIM Recognized Rent Expense Associated with Operating Lease <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20240101__20240930_zTI3OTTC3hs3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td> </td><td> </td> <td colspan="2" id="xdx_494_20230101__20230930_zDEerU0nJsUd" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_z4nmxel6skb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease costs:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseCost_pn3n3_maLCzBan_zsdk9W45uZG6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">226</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">214</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzBan_zvageJeGouK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Short-term and variable lease costs</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">205</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">253</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzBan_zZ6TvucId2ae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total lease costs</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Classification of lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3pRw35uNfzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Research & development</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0Zk0RR1SeEd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">General and administrative</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_zpv8JbELhHWh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total lease costs</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467</td><td style="text-align: left"> </td></tr> </table>

226000

214000

205000

253000

431000

467000

358000

400000

73000

67000

431000

467000

P6M

P35M

P32M

P41M

0.102

0.10

Future minimum payments as of September 30, 2024, are as follows: Schedule of Operating Lease Future Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td> </td> <td colspan="2" id="xdx_499_20240930_zfOCBbh5b624" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zwSmoTAsuoMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">78</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zo2ACskIj2Qi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Remainder year</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">78</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zG5gFMTW9ikh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zS98VF0BHrU2" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year one</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zO1zmA5VOGjd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zdqBlEQ5CUp8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zFVVWdKsf0g1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zNiQ2sSMMXGg" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_zohhKwodUyE1" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_zjlMJs4DZV7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zl1WmhMJO9tl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(88</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zCm8nqEVfErg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">669</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

78000

276000

244000

159000

88000

669000

Note 14: Research, Consulting and Supply Agreements The Company has entered into research, consulting and supply agreements with third party service providers to perform research and development activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred. During the three months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($582,000), manufacturing and engineering ($306,000), quality control ($398,000) and regulatory ($151,000). During the three months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($1,916,000), manufacturing and engineering ($396,000), quality control ($251,000) and regulatory ($170,000). During the nine months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($1,880,000), manufacturing and engineering ($882,000), quality control ($1,232,000) and regulatory ($540,000). During the nine months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($3,845,000), manufacturing and engineering ($2,783,000), quality control ($752,000) and regulatory ($359,000). The following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related to research and development costs for the nine months ended September 30, 2024. Amarex Clinical Research LLC Amarex is the principal administrator of several of AIM’s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research LLC (“Amarex”). During the three months ended September 30, 2024 and 2023, the Company incurred approximately $275,400 and $516,284, respectively, related to these ongoing agreements. During the nine months ended September 30, 2024 and 2023, the Company incurred approximately $881,987 and $1,294,265, respectively, related to these ongoing agreements: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pancreatic Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex’s management of the study will cost approximately $8,400,000. This estimate includes pass-through costs of approximately $1,000,000 and excludes certain third-party and investigator costs and escalations necessary for study completion. AIM anticipates that the study will take approximately <span id="xdx_907_ecustom--ResearchAndDevelopmentExpenseCostEstimatedLives_dtY_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zs1rZ6OYVwxa" title="Research and development expense cost">4.6 years to complete.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zPMxjNbFMZJh">129,000 related to this agreement. During the three months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zfeeqhHOLYG5">82,600 related to this agreement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zG31AwmZq5P3">141,100 related to this agreement. During the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_z1q1nkd6jsp5">350,600 related to this agreement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Post-COVID Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $6,400,000, which includes pass through costs of approximately $125,000, investigator costs estimated at about $4,400,000 and excludes certain other third-party costs and escalations. During 2023, the original work order increased to approximately $6,600,000 for the addition of patient reported outcome (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated with the ePRO system and additional safety monitoring services as well as changes to study documentation (such as protocol amendments) which resulted in additional IND submissions to FDA. This study was completed in 2023, although certain activities are still ongoing.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zzwC0omYI5Fk">27,500 related to this agreement. During the three months ended September 30, 2023, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zKfmtSA1QyB7">447,600 related to this agreement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zUAvqKyWhV9d">195,800 related to this agreement. During the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zkZx6pQrBXF9">783,400 related to this agreement.</td></tr></table> Jubilant HollisterStier Jubilant HollisterStier (“Jubilant”) is AIM’s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen® for the Company. Since the 2017 engagement of Jubilant, two lots of Ampligen consisting of more than 16,000 units were manufactured and released in the year 2018. The first lot was designated for human use in the United States in the cost recovery CFS program and for expanded oncology clinical trials. The second lot has been designated for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant manufactured additional two lots of Ampligen in December 2019 and January 2020. In December 2023, Jubilant completed manufacturing of 9,042 vials of Ampligen for clinical use. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the three months ended September 30, 2024, the Company did <span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20240701__20240930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zd7Xy1vOyrR6">not incur any expense related to this agreement. During the three months ended September 30, 2023, the Company did <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zT4YJsfc8UBf">not incur any expense related to this agreement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zr5aN8UyKlA2">1,200 related to this agreement. During the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zA9ohgAhx0ck">1,432,000 related to this agreement.</td></tr></table> Sterling Pharma Solutions In 2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (“Sterling”) for the manufacture of the Company’s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_z7DbKXwdCOX4">133,000 related to this agreement. During the three months ended September 30, 2023, the Company did <span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zE56Y1J9FBpf">not incur any expense related to this agreement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_z5JuugVYuFfk">261,600 related to this agreement. During the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zuA6kpr77eg2">357,000 related to this agreement.</td></tr></table> Erasmus In December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM’s limited responsibilities are limited to providing Ampligen. Additionally, in April 2023 AIM agreed to provide to Erasmus MC an unrestricted grant of $<span id="xdx_903_eus-gaap--SuppliesExpense_pp0p0_c20230401__20230430__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_z7O3hYhkXxHk">200,000 for immune monitoring in pancreatic cancer patients. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the three months ended September 30, 2024, the Company did <span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20240701__20240930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_ziXn8oDJb23l">not incur any expense related to this agreement. During the three months ended September 30, 2023, the Company did <span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zaxmqBcY8vRl">not incur any expense related to this agreement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zk7nDOkwB5Zg">79,000 related to this agreement. During the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zajwWSFsXS9g">100,000 related to this agreement.</td></tr></table> Azenova Sales International In October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development services for AIM’s Ampligen product for solid tumors for a 12-month term that is extendable upon the agreement of the parties. In exchange for its services, Azenova will receive a fixed monthly retainer of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20231031__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zERemEyApHXh">30,000 per month in addition to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pp0p0_c20231031__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z5z9qgncyonk">360,000 stock options that vest monthly. In August 2024, an agreement was made to reduce the fixed monthly retainer fee to $<span id="xdx_90D_ecustom--MonthlyRetainerFee_pp0p0_c20240801__20240831__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zBKN9omy6QG5" title="Monthly retainer fee">10,000. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zw3TeYRvVbif">50,000 related to this agreement. During the three months ended September 30, 2023, the Company did <span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHDu2ilh8y6l">not incur any expense related to this agreement.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zyLJ2J5JZ1sg">230,000 related to this agreement. During the nine months ended September 30, 2023, the Company did <span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230101__20230930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zPsV8praX1a3">not incur any expense related to this agreement.</td></tr></table> Alcami In September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging component. The agreement called for fixed costs of approximately $30,000 upon completion of the study and issue of the final report, along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received in December 2023. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the three months ended September 30, 2024, the Company did not incur any expense for lab services from Alcami. During the three months ended September 30, 2023, the Company incurred approximately $8,800 of lab services from Alcami.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the nine months ended September 30, 2024, the Company incurred approximately $14,000 of lab services from Alcami. During the nine months ended September 30, 2023, the Company incurred approximately $25,000 of lab services from Alcami.</td></tr></table>

582000

306000

398000

151000

1916000

396000

251000

170000

1880000

882000

1232000

540000

3845000

2783000

752000

359000

275400

516284

881987

1294265

8400000

1000000

P4Y7M6D

129000

82600

141100

350600

6400000

125000

4400000

6600000

27500

447600

195800

783400

16000 9042

1200

1432000

133000

261600

357000

200000

79000

100000

30000

360000

10000

50000

230000

30000

8800

14000

25000

Note 15: Subsequent Events On September 30, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) to complete an offering (the “Transactions”) with a single accredited investor (the “Purchaser”). The Transactions closed on October 1, 2024. Pursuant to the Purchase Agreement, at closing, the Company issued to the Purchaser, (i) in a registered direct offering, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx00GvBaYtf8">4,653,036 shares of the Company’s common stock (the “Shares”), par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoVgIkZB8Qn1">0.001 per share (“Common Stock”); and (ii) in a concurrent private placement, the Company issued to the Purchaser Class C common warrants to purchase an aggregate of up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2scs6y8z3O1">4,653,036 shares of its Common Stock (the “C Warrants”) at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGzc24PkOgwj">0.28 per share and Class D common warrants to purchase an aggregate of up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassDCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOmoY0HHQ79h">4,653,036 shares of its Common Stock (the “D Warrants” and, along with the C Warrants, the “Common Warrants”) at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassDCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpvPwH27tzRc">0.28 per share. The C Warrants and D Warrants will not be exercisable for six months after the issuance date and will expire, respectively, 24 months and five years and six months after the issuance date. The Common Warrants and the shares of Common Stock issuable upon the exercise of such warrants were offered pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The Company received aggregate gross proceeds from the Transactions of approximately $1.26 million, before deducting fees to the Placement Agent and other estimated offering expenses payable by the Company. The shares underlying the Common Warrants are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective on February 4, 2022 (as amended from time to time, the “Registration Statement”). Pursuant to the terms of the Purchase Agreement, subject to certain exceptions, the Company cannot issue any equity securities for 60 days following the closing of the Transactions (the “Closing Date”), provided that the Company will be able to utilize it’s at-the-market offering (the “ATM”) program with the Placement Agent after 30 days. Additionally, the Company cannot enter into a variable rate transaction (other than the ATM program with the Placement Agent) for 120 days after the Closing Date. In addition, the Company’s executive officers and each of the Company’s directors have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the Closing Date, offer, sell, transfer or otherwise dispose of the Company’s securities, subject to certain exceptions. The exercise price of the Common Warrants, and the number of shares of Common Stock underling the Common Warrant (the “Common Warrant Shares”) will be subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity had been named in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants will be exercisable on a “cashless” basis only if there is not a current registration statement permitting public resale. In this regard, the Company has agreed to file a registration statement to register the resale of the Common Warrant Shares as soon as practicable (and in any event within 45 calendar days of the date of the Purchase Agreement) providing for the resale of the Shares issued and issuable upon exercise of the Common Warrants. The Company has agreed to use commercially reasonable efforts to cause such registration statement to become effective within 181 days following the Closing Date and to keep such registration statement effective at all times until no Purchaser owns any Common Warrants or Common Warrant Shares issuable upon exercise thereof. The Company is currently evaluating the Common Warrants under the guidance of ASC 480 – Distinguishing Liabilities from Equity

4653036

0.001

4653036

0.28

4653036

0.28

1260000

5439000

27053000

7631000

7137000

1184000

1676000

302000

455000

14556000

36321000

127000

195000

697000

829000

2313000

1941000

1688000

1202000

19381000

40488000

6443000

377000

1986000

806000

223000

178000

8652000

1361000

495000

659000

9147000

2020000

0.001

4000000

250000

1000 1000

10000

689

696

689000

696000

0.001

350000000

49102484

48084287

701667

694324

49000

48000

419004000

418270000

-409508000

-380546000

10234000

38468000

19381000

40488000

202000

141000

202000

141000

42000

10939000

6990000

21137000

13074000

32118000

20064000

-31916000

-19923000

200000

-1679000

1069000

629000

18000

3000

-35000

1667000 1490000

-28962000

-19445000

-0.60

-0.40

48585404

48047288

696000

48084287

48000

418270000

-380546000

38468000

1017399

1000

484000

485000

243000

-7000

798

7000

-28962000

689000

49102484

49000

419004000

-409508000

10234000

715000

47994672

48000

417217000

-361101000

56879000

715000

47994672

48000

417217000

-361101000

56879000

88749

80000

954000

638

-19000

228

19000

-19445000

696000

48084287

48000

418270000

-380546000

38468000

696000

48084287

48000

418270000

-380546000

38468000

-28962000

-19445000

39000

38000

-35000

18000

14000

199000

218000

287000 -680000 -197000

243000

954000

200000

-1679000

-492000

35000

-153000

151000

-274000

688000

486000

83000

6066000

179000

1180000

368000

-21267000

-16108000

1299000

10083000

1593000

2724000

86000

47000

3900000

585000

185000

-832000

10988000

485000

80000

485000

80000

-21614000

-5040000

27053000

32093000

5439000

27053000

376000 -928000 7000 19000 73000 736000

(1) Description of Business and Basis of Presentation Business and Basis of Presentation Business AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection (Interferon Alfa-N3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). The Company’s primary business focus involves Ampligen. Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. AIM currently is proceeding primarily in four areas: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Conducting a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced pancreatic cancer patients.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Evaluating Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to check point inhibitors.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or Post-COVID conditions of fatigue.</td></tr> </table> AIM is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. AIM intends that priority clinical work be conducted in trials authorized by the U.S. Food and Drug Administration (“FDA”) or European Medicines Agency (“EMA”), which trials support a potential future NDA. However, the Company’s antiviral experimentation is designed to accumulate additional preliminary data supporting the hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, the Company will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data, including foreign venues. Basis of Preparation and Consolidation The accompanying consolidated financial statements include the accounts of AIM ImmunoTech and all entities in which a controlling interest is held by the Company. All significant intercompany balances and transactions have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”).

(2) Summary of Significant Accounting Policies (a) Cash and Cash Equivalents Cash includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $250 thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal. (b) Marketable Investment The Company’s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments using the specific identification method and measure the fair value of our marketable investments using a market approach where identical or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models. (c) Property and Equipment, net Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to ten years. Depreciation expense for the years ended December 31, 2023 and 2022 was $39,000 and $38,000, respectively. The Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $1,800,000 during the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022. (d) Patent and Trademark Rights, net Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful life of 17 years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value, or their value has become impaired. Such review includes an analysis of the patent and trademark’s ultimate revenue and profitability potential. Management’s review addresses whether each patent continues to fit into the Company’s strategic business plans. (e) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals. (f) Revenue The Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Revenue from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped. The Company has no other obligation associated with its products once shipment has been accepted by the customer. Revenue from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery program. (g) Accounting for Income Taxes Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material change to the Company’s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at this time. (h) Recent Accounting Standards and Pronouncements In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements. The standard requires additional or amended disclosure requirements for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective dependent upon the SEC’s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures. The amendments in this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements. Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company’s present or future financial statements. (i) Stock-Based Compensation The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, “Compensation – Stock Compensation”, which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net of estimated forfeitures. (j) Common Stock Per Share Calculation Basic and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period. Equivalent Common shares, consisting of 3,523,949 and 2,966,538 of stock options and warrants, are excluded from the calculation of diluted net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss of the Company. (k) Long-Lived Assets The Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. When assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping’s carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. The Company measures the impairment by comparing the difference between the asset grouping’s carrying value and its fair value. Long-lived assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated, it accelerates the rate of depreciation over the assets’ new, shorter useful lives. (l) Lease accounting The Company is a party to leases for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases, which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease term. The lease term is defined as the non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs, are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease liability, while any variable portion is recognized as variable lease expenses as incurred. The Company has elected not to recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term. (m) Reclassifications Certain prior year amounts have been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders’ equity, or cash flows.

(a) Cash and Cash Equivalents Cash includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $250 thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.

250000

(b) Marketable Investment The Company’s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments using the specific identification method and measure the fair value of our marketable investments using a market approach where identical or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.

(c) Property and Equipment, net Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to ten years. Depreciation expense for the years ended December 31, 2023 and 2022 was $39,000 and $38,000, respectively. The Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $1,800,000 during the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022.

Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

1448000

2233000

1321000

2038000

127000

195000

P10Y

39000

38000

1800000

(d) Patent and Trademark Rights, net Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful life of 17 years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value, or their value has become impaired. Such review includes an analysis of the patent and trademark’s ultimate revenue and profitability potential. Management’s review addresses whether each patent continues to fit into the Company’s strategic business plans.

P17Y

(e) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.

(f) Revenue The Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Revenue from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped. The Company has no other obligation associated with its products once shipment has been accepted by the customer. Revenue from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery program.

(g) Accounting for Income Taxes Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material change to the Company’s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at this time.

(h) Recent Accounting Standards and Pronouncements In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements. The standard requires additional or amended disclosure requirements for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective dependent upon the SEC’s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures. The amendments in this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements. Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

(i) Stock-Based Compensation The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, “Compensation – Stock Compensation”, which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net of estimated forfeitures.

(j) Common Stock Per Share Calculation Basic and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period. Equivalent Common shares, consisting of 3,523,949 and 2,966,538 of stock options and warrants, are excluded from the calculation of diluted net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss of the Company.

3523949

2966538

(k) Long-Lived Assets The Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. When assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping’s carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. The Company measures the impairment by comparing the difference between the asset grouping’s carrying value and its fair value. Long-lived assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated, it accelerates the rate of depreciation over the assets’ new, shorter useful lives. (l) Lease accounting The Company is a party to leases for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases, which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease term. The lease term is defined as the non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs, are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease liability, while any variable portion is recognized as variable lease expenses as incurred. The Company has elected not to recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term. (m) Reclassifications Certain prior year amounts have been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders’ equity, or cash flows.

<p id="xdx_804_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zTbja26Cmuk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(3) Marketable Investments Marketable Securities Marketable investments consist of mutual funds. At December 31, 2023 and 2022, it was determined that none of the marketable investments had an other-than-temporary impairment. At December 31, 2023 and 2022, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 15: Fair Value). As of December 31, 2023 and 2022, the Company held $7,631,000 and $7,137,000, respectively, in mutual funds. Mutual Funds classified as available for sale consisted of: (in thousands) December 31, 2023 Schedule of Available of Sale <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ztDUABWpr1K7" style="border-bottom: Black 1pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" style="border-bottom: Black 1pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Totals</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table> (in thousands) December 31, 2023 Schedule of Equity Securities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black; text-align: left">Net gain recognized during the year on equity securities</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">200</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the year on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(176</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the year on equity securities still held at the end of the year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">376</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> Mutual Funds classified as available for sale consisted of: <div id="xdx_C02_gL3IITB-MRQXJLX_zRHdn8ayZMe7" style="margin: 0pt"> (in thousands) December 31, 2022 <table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Available of Sale (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" style="border-bottom: Black 1pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" style="border-bottom: Black 1pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Totals</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> </div> (in thousands) <div id="xdx_C09_gL3TSACTATB-ODD_zph8HTxAKTql" style="margin: 0pt">December 31, 2022 <table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Equity Securities (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black; text-align: left">Net losses recognized during the period on equity securities</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(1,679</td><td style="width: 1%; color: Black; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the period on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(751</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(928</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> </table> </div>

7631000

7137000

Mutual Funds classified as available for sale consisted of: (in thousands) December 31, 2023 Schedule of Available of Sale <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_ztDUABWpr1K7" style="border-bottom: Black 1pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" style="border-bottom: Black 1pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Totals</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table> Mutual Funds classified as available for sale consisted of: (in thousands) December 31, 2022 <table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Available of Sale (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" style="border-bottom: Black 1pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" style="border-bottom: Black 1pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Totals</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

7631000

Schedule of Equity Securities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black; text-align: left">Net gain recognized during the year on equity securities</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">200</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the year on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(176</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the year on equity securities still held at the end of the year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">376</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> (in thousands)December 31, 2022 <table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Equity Securities (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black; text-align: left">Net losses recognized during the period on equity securities</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(1,679</td><td style="width: 1%; color: Black; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the period on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(751</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">(928</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> </table>

200000

-176000

376000

7137000

-1679000

-751000

-928000

(4) Patents and Trademark Rights, Net Patents, and Trademark Rights, Net Patent and trademark rights consist of the following (in thousands): Schedule of Patent and Trademark Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" style="width: 6%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" style="width: 6%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" style="width: 6%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" style="width: 6%; text-align: right" title="Gross carrying value">2,389</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" style="width: 6%; text-align: right" title="Accumulated amortization">(595</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" style="width: 6%; text-align: right" title="Net carrying value">1,794</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">116</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">216</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(69</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">147</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(664</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,941</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table presents the changes in the patents and trademark rights: Schedule of Changes in Patents, Trademark Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: right"> </td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: right">(in thousands)</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black">December 31, 2022</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" style="width: 14%; color: Black; text-align: right" title="Beginning balance">1,941</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Acquisitions</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" style="color: Black; text-align: right" title="Acquisitions">585</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Abandonments</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" style="color: Black; text-align: right" title="Abandonments">(14</td><td style="color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Amortization</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Accumulated Amortization">(199</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance">2,313</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method of the estimated useful life of 17 years and 10 years, respectively. <p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Amortization of patents and trademarks for each of the next five years is as follows (in thousands): Schedule of Amortization of Patents and Trademarks <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zRpq4JAtM4eg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year one</td><td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">241</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_za9itkNejeW7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year two</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zh3zXd7nkJv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">230</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year three</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">230</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zBPrm1D36gxb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">208</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year four</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">208</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_z4MVHNpH3vgb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year five</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zWzIQBUJLgzc" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Year seven</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Patent and trademark rights consist of the following (in thousands): Schedule of Patent and Trademark Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" style="width: 6%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" style="width: 6%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" style="width: 6%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" style="width: 6%; text-align: right" title="Gross carrying value">2,389</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" style="width: 6%; text-align: right" title="Accumulated amortization">(595</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" style="width: 6%; text-align: right" title="Net carrying value">1,794</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">116</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">216</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(69</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">147</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(664</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,941</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2947000

-750000

2197000

2389000

-595000

1794000

229000

-113000

116000

216000

-69000

147000

3176000

-863000

2313000

2605000

-664000

1941000

Schedule of Changes in Patents, Trademark Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: right"> </td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: right">(in thousands)</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black">December 31, 2022</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" style="width: 14%; color: Black; text-align: right" title="Beginning balance">1,941</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Acquisitions</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" style="color: Black; text-align: right" title="Acquisitions">585</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Abandonments</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" style="color: Black; text-align: right" title="Abandonments">(14</td><td style="color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Amortization</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Accumulated Amortization">(199</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance">2,313</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

1941000

585000

14000

199000

2313000

P17Y

P10Y

<p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Amortization of patents and trademarks for each of the next five years is as follows (in thousands): Schedule of Amortization of Patents and Trademarks <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zRpq4JAtM4eg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year one</td><td style="text-align: left"> </td> <td style="text-align: left">$</td><td style="text-align: right">241</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_za9itkNejeW7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year two</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zh3zXd7nkJv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">230</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year three</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">230</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zBPrm1D36gxb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">208</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year four</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">208</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_z4MVHNpH3vgb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year five</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zWzIQBUJLgzc" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Year seven</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

241000

232000

230000

208000

189000

1213000

2313000

(5) Accrued Expenses Accrued expenses at December 31, 2023 and 2022 consist of the following: Schedule of Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black">Compensation</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">414</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Professional fees</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">1,352</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">492</td><td style="color: Black; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Clinical trial expenses</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">184</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">110</td><td style="color: Black; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Other expenses</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">36</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">203</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Total</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">806</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

Accrued expenses at December 31, 2023 and 2022 consist of the following: Schedule of Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black">Compensation</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">414</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Professional fees</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">1,352</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">492</td><td style="color: Black; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Clinical trial expenses</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">184</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">110</td><td style="color: Black; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Other expenses</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">36</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">203</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Total</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">806</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

414000

1000

1352000

492000

184000 110000

36000

203000

1986000

806000

(6) Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 shares of $0.01 par value preferred stock with such designations, rights and preferences as may be determined by the Board. Of our authorized preferred stock, <span id="xdx_906_ecustom--PreferredStockSharesDesignated_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zdxw96RmwE92" title="Preferred stock shares designated">4,000,000 shares have been designated as Series A Junior Participating Preferred Stock and 10,000 shares have been designated as Series B Convertible Preferred Stock. Series A Junior Participating Preferred Stock On May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series A Junior Participating Preferred Stock to <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zvXQMF6jp4Uc" title="Preferred stock, shares authorized">4,000,000 from <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zFqCvlwtYRY8" title="Preferred stock, shares authorized">250,000 shares. Series B Convertible Preferred Stock The Company has designated 10,000 shares of its preferred stock as Series B Convertible Preferred Stock (the “Preferred Stock”). Each share of Preferred Stock has a par value of $0.01 per share and a stated value equal to $<span id="xdx_90E_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z2ifv33uJKaa" title="Preferred stock, stated value">1,000 (the “Stated Value”). The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of the shares of Preferred Stock. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option of the Corporation, into that number of shares of Common Stock (subject in each case to the limitations determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $0.20, subject to adjustment herein (the “Conversion Price”). Pursuant to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock with a face value of $<span id="xdx_906_ecustom--FaceValueOfStock_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zcT2YZJIvmV1" title="Preferred stock face value">1,000 (and immediately convertible into common stock at an assumed conversion price of $8.80) and 114 warrants with an assumed exercise price of $8.80. The redeemable warrants are exercisable for five years after the date of issuance. The net proceeds realized from the rights offering were approximately $4,700,000. During the year ended December 31, 2023, 7 shares of Series B Convertible Preferred Stock were converted into common stock. As of December 31, 2023 and 2022, the Company had 689 and 696 shares of Series B Convertible Preferred Stock outstanding, respectively. Holders shall be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividend actually paid on shares of Common Stock when as and if such dividends are paid on shares of the Common Stock. Each such Preferred Share is convertible into 114 shares of common stock. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the Holders shall be entitled to receive out of the assets, whether capital or surplus of the Company the same amount that a holder of Common Stock would receive if the Preferred Stock was fully converted. The Series B Convertible Preferred Stock does not carry voting Rights. (b) Common Stock and Equity Finances The Company has authorized shares of 350,000,000 with specific limitations and restrictions on the usage of 8,000,000 of the 350,000,000 authorized shares. As of December 31, 2023 and 2022, there were 49,102,484 and 48,084,287 shares of Common Stock issued and outstanding, respectively. Employee Stock Purchase Plan (Not equity compensation) On July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $500,000 worth of shares at the market price (including subsequent plans, the “Employee Stock Purchase Plan”). Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved the Company’s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7, 2020 plan. The latest plan was approved by the Board in January 2024 and expires in March 2024. During the year ended December 31, 2023, the Company issued a total of 419,285 shares of its Common Stock at a price ranging from $0.31 to $0.67 for total proceeds of approximately $150,500 as part of the employee stock purchase plan. During the year ended December 31, 2022, the Company issued a total of 86,817 shares of its Common Stock at prices ranging from $0.76 to $1.02 for total proceeds of $80,000 as part of the employee stock purchase plan. Warrants (Rights offering) On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 shares of Common Stock; (ii) pre-funded warrants exercisable for 7,148,310 shares of Common Stock (the “Pre-funded Warrants”), and (iii) warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zZktK4vOrA5a">8,888,860 shares of Common Stock (the “Warrants”). In conjunction with the Offering, we issued a Representative’s Warrant to purchase up to an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zcUVBXAOEfFe">266,665 shares of common stock (the “Representative’s Warrant”). The shares of Common Stock and Warrants were sold at a combined Offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zG0XCk86BvSl">0.90, less underwriting discounts and commissions. Each Warrant sold with the shares of Common Stock represents the right to purchase one share of Common Stock at an exercise price of $0.99 per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $0.899, less underwriting discounts and commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of Common Stock in the Offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than <span id="xdx_90D_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zn1SmfFvg678" title="Percentage of outstanding stock">4.99% of the Company’s outstanding Common Stock immediately following the consummation of the Offering, in lieu of shares of Common Stock. Each Pre-Funded Warrant represents the right to purchase one share of Common Stock at an exercise price of $0.001 per share. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1, relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately $7,200,000. During the year ended December 31, 2020, 1,870,000 of the Pre-funded Warrants were exercised and 8,873,960 Warrants were exercised. In addition, on March 25, 2020, the Representative’s Warrant was amended to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020 and an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zBNFf2hF7fXf">266,665 shares were issued upon exercise of this warrant for gross proceeds of approximately $264,000 and a $46,000 expense for the warrant modification. No Warrants were exercised during the year ended December 31, 2023 and 2022. As of December 31, 2023 and 2022 there are 15,000 Warrants outstanding. Equity Distribution Agreement On April 19, 2023, the Company entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $8,500 000 through Maxim, as agent (the “Offering”). Sales under the EDA were registered under the S-3 Shelf Registration Statement. Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of 3.0% of the gross sales price of shares sold under the EDA. During the year ended December 31, 2023, the Company sold 598,114 shares under the EDA for total gross proceeds of approximately $344,000, which includes a 3.0% fee to Maxim of $10,326. Subsequent to the year ended December 31, 2023, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDyG2c83P0r1">699,568 shares under the EDA for total gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRQPJ8F7ZeUj">316,392, which includes a <span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBW1BZtSXEI7">3.0% fee to Maxim of $9,492. Rights Plan On May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer & Trust Company as Rights Agent (the “Rights Plan”). (c) Common Stock Options and Warrants (i) Stock Options The 2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of 7,000,000 shares of common stock is reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. Unless sooner terminated, the 2018 Equity Incentive Plan will continue in effect for a period of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zJTZfbENHDnc">10 years from its effective date. The Equity Incentive Plan of 2018 is administered by the Board of Directors. The Plan provides for awards to be made to such Officers, other key employees, non-employee Directors, consultants and advisors of the Company and its subsidiaries as the Board may select. Stock options awarded under the Plan may be exercisable at such times (not later than 10 years after the date of grant) and at such exercise prices (not less than fair market value at the date of grant) as the Board may determine. The Board may provide for options to become immediately exercisable upon a “change in control”, which is defined in the Plan to occur upon any of the following events: (a) the acquisition by any person or group, as beneficial owner, of 20% or more of the outstanding shares or the voting power of the outstanding securities of the Company; (b) either a majority of the Directors of the Company at the annual stockholders meeting has been nominated other than by or at the direction of the incumbent Directors of the Board, or the incumbent Directors cease to constitute a majority of the Company’s Board; (c) the Company’s stockholders approve a merger or other business combination pursuant to which the outstanding common stock of the Company no longer represents more than 50% of the combined entity after the transaction; (d) the Company’s stockholders approve a plan of complete liquidation or an agreement for the sale or disposition of all or substantially all of the Company’s assets; or (e) any other event or circumstance determined by the Company’s Board to affect control of the Company and designated by resolution of the Board as a change in control. The fair value of each option award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, life and forfeiture rates. The expected life of the options and equity warrants was estimated based on historical option and equity warrant holders’ behavior and represents the period of time that options and equity warrants are expected to be outstanding. The fair values of the options granted were estimated based on the following weighted average assumptions: <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Schedule of Options and Equity Estimated Based on Weighted Average Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Risk-free interest rate</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zdgMbROP6A7d" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">4.37</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z9TOSO7jOfv" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Risk-free interest rate">1.74% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zAoLYTXAFZH4" title="Risk-free interest rate">3.88%</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expected dividend yield</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zdg3IpXfgy3h" style="color: Black; text-align: right" title="Expected dividend yield">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" style="color: Black; text-align: right" title="Expected dividend yield">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Expected life</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z3xuQ8EFJrAi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Expected life">10 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ztYz1bcbx4Af" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Expected life">10 years</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expected volatility</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zNAPI7Mt8sRe" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">99.91</td><td style="color: Black; text-align: left">%</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zpwZnKI2Kqia" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Expected volatility">98.43% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zUb8eXULgQZ8" title="Expected volatility">107.18%</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Weighted average grant date fair value for options issued</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zCcQLirietJa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average grant date fair value for options issued">$0.43 per option for 400,000 options</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zKVhEap8WyD" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average grant date fair value for options issued">$0.51 per option for 850,000 options</td><td style="color: Black; text-align: left"> </td></tr> </table> The exercise price of all stock options and equity warrants granted was equal to or greater than the fair market value of the underlying common stock on the date of the grant. <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Information regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June 24, 2019: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_ztXYC5RXvHid" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">124,399</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zEaNTJpnrRz9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, beginning of year">13.20 – <span id="xdx_90F_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_z7YVsfmrA434" title="Option price outstanding, beginning of year">1,003.20</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">22.23</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">128,504</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zF91QAWuEQcg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, beginning of year">13.20 – <span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_z0tjKmB8ODje" title="Option price outstanding, beginning of year">2,127.84</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">25.58</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" style="color: Black; text-align: right" title="Number of options, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" style="color: Black; text-align: right" title="Option price, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" style="color: Black; text-align: right" title="Weighted average exercise price, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" style="color: Black; text-align: right" title="Number of options, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zeVmlm4aMdgc" style="color: Black; text-align: right" title="Option price, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" style="color: Black; text-align: right" title="Weighted average exercise price, granted">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" style="color: Black; text-align: right" title="Number of options, forfeited">(5,047</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhl7KQbcb05h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, forfeited">9.68-<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zaGeAynr79Y" title="Option price, forfeited">327.36</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">57.79</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" style="color: Black; text-align: right" title="Number of options, forfeited">(4,105</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk8RmfPhWhol" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, forfeited">16.76-<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_ztQRdiSx1M9k" title="Option price, forfeited">2,127.84</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">129.88</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEA96KOpuai1" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Option price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zhffRuieaXM2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Option price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">119,352</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_900_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhrkQSIS56hc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">13.20-<span id="xdx_90F_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_z7lI5N5h2MQ5" title="Option price exercisable, end of year">2,127.84</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">20.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">124,399</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zjCLjhx8fDPf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">13.20-<span id="xdx_905_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zdSF5I9EHrBd" title="Option price exercisable, end of year">1,003.20</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">22.23</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" style="color: Black; text-align: right" title="Number of options exercisable, end of year">119,352</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zWThkgMqF8Vl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">13.20-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpqLPr0a8Lf4" title="Option price exercisable, end of year">2,127.84</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" style="color: Black; text-align: right" title="Number of options exercisable, end of year">124,399</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zegZseD63ARj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">13.20-<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zdt9X9KjYPHa" title="Option price exercisable, end of year">1,003.20</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; color: Black; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z9Mykpb2QCQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life (years)">4.06 years</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; color: Black; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zGc1vLLZsSUh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life (years)">5.98 years</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Information regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWkNWefe0Xh5" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,474,971</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">0.31-9.68</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">1.72</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,650,017</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="white-space: nowrap; width: 7%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zycM5coCDmZ6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, beginning of year">1.11 – <span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zo3YUK4euDAg" title="Option price outstanding, beginning of year">9.68</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">2.35</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zPCdlU64INS" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">0.47-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zPY5yYMHaoh5" title="Option price, granted">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" style="color: Black; text-align: right" title="Number of options, granted">850,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIDoTWdBMzKi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, granted">0.31 – <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zUhIdoaKAeM5" title="Option price, granted">1.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.51</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" style="color: Black; text-align: right" title="Number of options, forfeited">(60,829</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z3aZJd8umXH6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, forfeited">0.31-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zUQl9ptUUdg7" title="Option price, forfeited">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.98</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" style="color: Black; text-align: right" title="Number of options, forfeited">(25,046</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zAUba1ObnkOl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, forfeited">1.85 – <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zSdlqpKHm0Vb" title="Option price, forfeited">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSJNjeMW9QCj" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.86</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Option price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSmCOnPdjGs1" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Option price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zJJDhGvlGta9" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znPAgqne0pt2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,814,142</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zepL3rOEQOMh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, end of year">0.31-<span id="xdx_908_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zjopxTDNLZyb" title="Option price outstanding, end of year">9.68</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zj4jXu1T0o88" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.54</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,474,971</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zdVP2wqybK1l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, end of year">0.31 – <span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zkyAAoDzVPXl" title="Option price outstanding, end of year">9.68</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" style="color: Black; text-align: right" title="Number of options exercisable, end of year">2,397,474</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">0.31-<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e">327.36</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z5f85g1G8ZKe" style="color: Black; text-align: right" title="Weighted average exercise price exercisable end of year">4.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" style="color: Black; text-align: right" title="Number of options exercisable, end of year">1,916,637</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zg2M3pcSmdEk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">0.41 – <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z5R9lpc6C103" title="Option price exercisable, end of year">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zmaoDrlHSq71" style="color: Black; text-align: right" title="Weighted average exercise price exercisable end of year">2.22</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="white-space: nowrap; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zeNewBk1Knul" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life (years)">7.96 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="white-space: nowrap; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zURhk2jYyOBh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life (years)">9.65 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Available for future grants</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvElgq65fgQ7" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Available for future grants">1,210,286</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z5Wcr81lQ78i" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Available for future grants">466,120</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table> Stock option activity during the years ended December 31, 2023 and 2022 is as follows: <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Vested stock option activity for employees: Schedule of Vest Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7Cd1KIdDn5l" style="width: 10%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,498,798</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJVgdwD4j8tf" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price beginning of year">4.22</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUg2ivYvgceb" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.11</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zriQd66kX1qh" style="width: 10%; color: Black; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" style="color: Black; text-align: right" title="Number of options, granted">550,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zr3ObctKwXT9" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price granted">0.49</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXJoC9BXIFn1" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) granted">9.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" style="color: Black; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWGVDwzHjio6" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price forfeited">17.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of Options, Expired">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZ2pms0MFVMe" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price expired">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,020,214</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHxOaM5i8Ezj" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price beginning of year">3.01</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zA90DMv1aJ6d" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.86</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRHqEs9Ma7Ai" style="color: Black; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTlgMLiQwZt1" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price granted">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFOBeabDTBij" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) granted">10.17</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" style="color: Black; text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6OqXjcptC3e" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price forfeited">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ztu0z0sxBWpf" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price expired">41.61</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh3hBmPzQlSi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,408,438</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zeJkOdNtZgz4" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price end of year">2.50</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3DsiWmxBJN9" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.70</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zj2dr0hydFpg" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV4OkEdjq75j" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options, vested and expected to vest">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z41h4Z90CFra" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price vested and expected to vest">1.90</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZcyMhukria7" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested and expected to vest">6.73</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZHxcS18IPmj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zK2mbJPKD8F8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options exercisable">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6UilfPMmP47" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price exercisable">1.90</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSf4JStBmGn6" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) exercisable">6.73</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztYawr6YP4m2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> The weighted-average grant-date fair value of employee options vested during the year ended December 31, 2023 was $184,000 for 424,999 options at $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwhJUHGEuao6">0.43 per option and during year ended December 31, 2022 was $768,666 for 575,000 options at $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIGmU7JOYkvk">1.34 per option. <p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted Average Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average Remaining Contracted Term</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left">Unvested December 31, 2021</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqWTzlDRCDh2" style="width: 13%; text-align: right" title="Number of options unvested, beginning of year">412,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Cz7FkU8xR3" style="width: 13%; text-align: right" title="Weighted average exercise price unvested, beginning of year">4.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ztN57QV8lJf4" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">5.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_znOirm9QawT" style="width: 13%; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRbJ5NwjXDB" style="text-align: right" title="Number of options, granted">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcnLUXLAuHKk" style="text-align: right" title="Weighted average exercise price granted">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zdvphGqGkGqd" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) granted">9.71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlaDllP3aiDd" style="text-align: right" title="Number of options, vested">(541,590</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrnsqmcvQFv4" style="text-align: right" title="Weighted average exercise price vested">1.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKmIlxvixTCa" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">9.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Forfeited</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNrTf165S871" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, forfeited">(28,584</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVRCs30iLe3e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price forfeited">17.71</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested December 31, 2022</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZUpZLtWnau1" style="text-align: right" title="Number of options unvested, beginning of year">392,326</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zioOSWL1jP5d" style="text-align: right" title="Weighted average exercise price unvested, beginning of year">0.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMldkN5sDIEi" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">8.86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNlUfk9xcEIg" style="text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZrSMXNIB9aj" style="text-align: right" title="Number of options, granted">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJewJEr9hh9d" style="text-align: right" title="Weighted average exercise price granted">0.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHF9II4neNva" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) granted">10.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zEjRTabmFlUb" style="text-align: right" title="Number of options, vested">(413,884</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zkce40uIATOk" style="text-align: right" title="Weighted average exercise price vested">1.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNjdm7kIIJga" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">6.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forfeited</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zg0xcWSOHoNi" style="text-align: right" title="Number of options, forfeited">(7,601</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu9xcnDbZEZ5" style="text-align: right" title="Weighted average exercise price forfeited">9.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Expired</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zDczHCvZIb14" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired">(4,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfLv6n2HQAZg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expired">41.61</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Unvested December 31, 2023</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zEyeHBhO90e3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options unvested, ending of year">366,666</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl1beeMK2ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">2.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfl08TREisY2" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, ending of year">12.44</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJYELYHWcOC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value unvested, ending of year">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Vested stock option activity for non-employees: Schedule of Vest Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEs2LdYztmZb" style="width: 13%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">279,723</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbvLwTLMhI8l" style="width: 13%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">6.12</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zppYmzF5aPvg" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">7.93</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqboIHm0MY2" style="width: 13%; color: Black; text-align: right" title="Aggregate intrinsic value outstanding, beginning of year">—</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8kopK3lZuE6" style="color: Black; text-align: right" title="Number of options, granted">300,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBv1bgg9mBO" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.54</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcLgCkuLQCSg" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), granted">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Exercised</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMmNo7h6qjN1" style="color: Black; text-align: right" title="Number of options, exercised">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNyz8BJgYqH4" style="color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zs7OEELu0YFf" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, forfeited">(568</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMT6Nq6PdVa3" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, forfeited">153.12</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zv5lIy8IM5qg" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">579,155</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBlcxqIXff21" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">3.09</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQPBSsmtmgob" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.36</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7JTnEGAAnp5" style="color: Black; text-align: right" title="Aggregate intrinsic value outstanding, beginning of year">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgtIaPy5L8R8" style="color: Black; text-align: right" title="Number of options, granted">360,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0j54vAfy8n7" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.46</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVALSScWmani" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), granted">10.04</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Exercised</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKpeQQtovmZ8" style="color: Black; text-align: right" title="Number of options, exercised">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWc8dBYMEW6a" style="color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black"> Expired</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFaHI1qW0eg5" style="color: Black; text-align: right" title="Number of options,expired">(653</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zt0TmBEtxrH1" style="color: Black; text-align: right" title="Weighted average exercise price, expired">145.24</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNgnlxZXCMz3" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zn7GHfNYV2nl" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYSnxO6m4KE8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">885,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBeQWeFrKmj8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">2.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zy2ut5eiqUp2" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMU5rcESbhCb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value outstanding, ending of year">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1ahHPoA8eol" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options, vested and expected to vest">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAmU6WfQaq9b" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, vested and expected to vest">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zySeEgubABYa" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) , vested and expected to vest">10.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_za63Mg8Lwn7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUgp16yefPv8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options exercisable, end of year">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zV73ZTvwI9M6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price exercisable, ending of year">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZSFdCo6pXL8" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), exercisable">10.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEL5mLEjXio3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> The weighted-average grant-date fair value of non-employee options vested during year 2023 was $90,000 for 191,666 options at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zSgr1cy7Cd98">0.47 per option and during the year 2022 was $247,166 for 229,053 options at $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zBl8iBiuAg14">1.08 per option. <p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; color: Black; text-align: left">Unvested December 31, 2021</td><td style="width: 2%; color: Black; text-align: left"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zk92jY3SKqgk" style="width: 13%; color: Black; text-align: right" title="Number of options unvested, beginning of year">97,831</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWcfpTfk0Zi9" style="width: 13%; color: Black; text-align: right" title="Weighted average exercise price unvested, beginning of year">3.89</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zugGZ42TVVFd" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual Term (years) beginning of year">7.82</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_znwVJlgZFZg8" style="width: 13%; color: Black; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Granted</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQKw4QeZCkD1" style="color: Black; text-align: right" title="Number of options granted">300,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzmg1kD0pWD9" style="color: Black; text-align: right" title="Weighted average exercise price granted">0.54</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWufgR11hSCb" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual Term (years) granted">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Vested</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabNQp6FtYf4" style="color: Black; text-align: right" title="Number of options vested">(229,053</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRrp4QjNHUK4" style="color: Black; text-align: right" title="Weighted average exercise price vested">0.82</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFqYIWTqJU11" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options forfeited">(1,989</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Unvested December 31, 2022</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztUgztRmpnqe" style="color: Black; text-align: right" title="Number of options unvested, beginning of year">166,789</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCfwWbqdgDK2" style="color: Black; text-align: right" title="Weighted Average Exercise Price Number of options unvested, beginning of year">4.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zmfc5mHCPaR5" style="font-family: Times New Roman, Times, Serif" title="Average Remaining Contractual Term (years) unvested, beginning of year">9.49</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zg20zTtksb9e" style="color: Black; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Granted</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0NWtJezinqf" style="color: Black; text-align: right" title="Number of options granted">360,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDYxe9GPcc62" style="color: Black; text-align: right" title="Weighted average exercise price granted">0.46</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoIHS4NGC1Od" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual Term (years) granted">10.18</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Vested</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaUTXaP94rH7" style="color: Black; text-align: right" title="Number of options vested">(137,565</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrkzKvozb3gf" style="color: Black; text-align: right" title="Weighted average exercise price vested">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTNTRx44LZsh" style="font-family: Times New Roman, Times, Serif" title="AWeighted average remaining contractual Term (years) vested">9.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expired</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaZW787Juujf" style="color: Black; text-align: right" title="Number of options expired">(776</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuk3FxuFZEh6" style="color: Black; text-align: right" title="Weighted average exercise price expired">145.24</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcJ6qQlusKrg" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTsjJ5Vjycl6" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price forfeited">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unvested December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQ2yciXIcXrb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options ending of year">335,001</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zveX3FSVK0o7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price ending of year">1.83</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbifrIOXXzVe" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual Term (years) uvested, ending of year">10.70</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvkmLL21RoE9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value unvested, ending of year">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> Stock-based compensation expense was approximately $243,000 and $954,000 for the years ended December 31, 2023 and 2022. As of December 31, 2023 and 2022, there was $294,000 and $217,000, respectively, of unrecognized stock-based compensation cost related to options granted under the Equity Incentive Plans. Stock-based compensation related to options granted under the Equity Incentive Plans will be recorded over the vesting period which is typically one year or upon reaching agreed upon Company and/or individual performance milestones being met which is indefinite. (ii) Stock Warrants Stock warrants are issued as needed by the Board of Directors and have no formal plan. The fair value of each warrant award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the warrant. The Company uses historical data to estimate expected dividend yield, life and forfeiture rates. The expected life of the warrants was estimated based on historical option holder’s behavior and represents the period of time that options are expected to be outstanding. No warrants were granted in 2023 or 2022. <p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Information regarding warrants outstanding and exercisable into shares of common stock is summarized below: Schedule of Warrants Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: justify">Outstanding, beginning of year </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB21PsJgzOzh" style="width: 8%; color: Black; text-align: right" title="Number of outstanding, beginning of year">226,610</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 8%; color: Black; text-align: right">$ <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjDTxWKhK3th" title="Warrant price beginning of the year">0.99-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAG5jyi4nDck" title="Warrant price beginning of the year">132.00</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3psSq5Dvm96" style="width: 8%; color: Black; text-align: right" title="Number of outstanding, beginning of year">294,939</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 8%; color: Black; text-align: right">$<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zgV7v3XqgwN" title="Warrant price beginning of the year">0.99 – <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zbiDReT7UGcc" title="Warrant price beginning of the year">469.92</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">15.19</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zndHzhSjjuf3" style="color: Black; text-align: right" title="Number of outstanding, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPjxUpQ74ohf" style="color: Black; text-align: right" title="Warrant price granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGL8jDnh9xA2" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyH1Cc623fNk" style="color: Black; text-align: right" title="Number of outstanding, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv2hDEBTlwMh" style="color: Black; text-align: right" title="Warrant price granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaMnmF2kIfN6" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, granted">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Expired</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfHx7AfC7Tij" style="color: Black; text-align: right" title="Number of outstanding, expired">(74,450</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSAJbBHEaA9" style="font-family: Times New Roman, Times, Serif" title="Warrant price expired">17.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxUQiCUef034" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, expired">17.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW7b5bVDXTth" style="color: Black; text-align: right" title="Number of outstanding, expired">(68,215</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23CecWIDAZ3" style="font-family: Times New Roman, Times, Serif" title="Warrant price expired">469.92</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z04DjcMYP5c8" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, expired">469.92</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQm1H88DK8oe" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of outstanding, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zConGTCMYuO8" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Warrant price exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZOmF4KMaBF2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbDzqKntwkl2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of outstanding, exercised">(114</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWKIwR0r00bk" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Warrant price exercised">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM03d6qDVpj" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, exercised">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQTQ7OTCKga6" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of outstanding, end of year">152,160</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">$ <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zAnLIGdZmAib" title="Warrant price end of the year">0.99-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z3vCgp9Au7va" title="Warrant price end of the year">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Ft54Be4PVf" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">8.03</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQPpCsmELAqd" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of outstanding, end of year">226,610</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">$ <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zhn74WMjmbtc" title="Warrant price end of the year">0.99-<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zZJ2dT7hECO" title="Warrant price end of the year">132.00</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6SQeeslPyf5" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">9.10</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zul2htOWCJ2g" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of outstanding, exercisable">152,160</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">$ <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWbaUGh8wkx9" title="Warrant price exercisable">0.99-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zdilkZuTsu38" title="Warrant price exercisable">8.80</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHuRrGG3YpL1" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price exercisable">8.03</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9eQX3lJjcle" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of outstanding, exercisable">226,610</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">$ <span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zakb5muf7gDl" title="Warrant price exercisable">0.99-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpoxQoeCYfch" title="Warrant price exercisable">132.00</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRfAmIe0oaP3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price exercisable">9.10</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Weighted average remaining contractual life</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1UI621XbpC7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life">.75 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoTdSyGyrkXj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life">.94 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Years exercisable</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJxcsQo69APg" style="font-family: Times New Roman, Times, Serif" title="Years exercisable">2024</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zUpRsQlGD8Gf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Years exercisable">2023-<span id="xdx_904_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5nXjHBfCTf5" title="Years exercisable">2024</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td></tr> </table> Stock warrants are issued at the discretion of the Board. During the year ended December 31, 2023, there were no warrants issued or exercised. During the year ended December 31, 2022, there were no warrants issued and 114 were exercised.

5000000

0.01

4000000

10000

4000000

250000

10000

0.01

1000

0.20

1000

8.80

114

8.80

P5Y

4700000

689

696

114

350000000

8000000

350000000

49102484

48084287

500000

419285

0.31

0.67

150500

86817

0.76

1.02

80000

1740550

7148310

8888860

266665

0.90

0.99

0.899

0.0499

0.001

7200000

1870000

8873960

266665

264000

46000

15000

8500

0.030

598114

344000

0.030

10326

699568

316392

0.030

9492

7000000

P10Y

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Schedule of Options and Equity Estimated Based on Weighted Average Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Risk-free interest rate</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zdgMbROP6A7d" style="font-family: Times New Roman, Times, Serif" title="Risk-free interest rate">4.37</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z9TOSO7jOfv" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Risk-free interest rate">1.74% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zAoLYTXAFZH4" title="Risk-free interest rate">3.88%</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expected dividend yield</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zdg3IpXfgy3h" style="color: Black; text-align: right" title="Expected dividend yield">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" style="color: Black; text-align: right" title="Expected dividend yield">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Expected life</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z3xuQ8EFJrAi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Expected life">10 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ztYz1bcbx4Af" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Expected life">10 years</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expected volatility</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zNAPI7Mt8sRe" style="font-family: Times New Roman, Times, Serif" title="Expected volatility">99.91</td><td style="color: Black; text-align: left">%</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zpwZnKI2Kqia" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Expected volatility">98.43% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zUb8eXULgQZ8" title="Expected volatility">107.18%</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Weighted average grant date fair value for options issued</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zCcQLirietJa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average grant date fair value for options issued">$0.43 per option for 400,000 options</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zKVhEap8WyD" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average grant date fair value for options issued">$0.51 per option for 850,000 options</td><td style="color: Black; text-align: left"> </td></tr> </table>

0.0437

0.0174

0.0388

P10Y

0.9991

0.9843

1.0718

$0.43 per option for 400,000 options $0.51 per option for 850,000 options

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Information regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June 24, 2019: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_ztXYC5RXvHid" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">124,399</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zEaNTJpnrRz9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, beginning of year">13.20 – <span id="xdx_90F_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_z7YVsfmrA434" title="Option price outstanding, beginning of year">1,003.20</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">22.23</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">128,504</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zF91QAWuEQcg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, beginning of year">13.20 – <span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_z0tjKmB8ODje" title="Option price outstanding, beginning of year">2,127.84</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">25.58</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" style="color: Black; text-align: right" title="Number of options, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" style="color: Black; text-align: right" title="Option price, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" style="color: Black; text-align: right" title="Weighted average exercise price, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" style="color: Black; text-align: right" title="Number of options, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zeVmlm4aMdgc" style="color: Black; text-align: right" title="Option price, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" style="color: Black; text-align: right" title="Weighted average exercise price, granted">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" style="color: Black; text-align: right" title="Number of options, forfeited">(5,047</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhl7KQbcb05h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, forfeited">9.68-<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zaGeAynr79Y" title="Option price, forfeited">327.36</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">57.79</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" style="color: Black; text-align: right" title="Number of options, forfeited">(4,105</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk8RmfPhWhol" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, forfeited">16.76-<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_ztQRdiSx1M9k" title="Option price, forfeited">2,127.84</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">129.88</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEA96KOpuai1" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Option price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zhffRuieaXM2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Option price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">119,352</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_900_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhrkQSIS56hc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">13.20-<span id="xdx_90F_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_z7lI5N5h2MQ5" title="Option price exercisable, end of year">2,127.84</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">20.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">124,399</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zjCLjhx8fDPf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">13.20-<span id="xdx_905_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zdSF5I9EHrBd" title="Option price exercisable, end of year">1,003.20</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">22.23</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" style="color: Black; text-align: right" title="Number of options exercisable, end of year">119,352</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zWThkgMqF8Vl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">13.20-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpqLPr0a8Lf4" title="Option price exercisable, end of year">2,127.84</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" style="color: Black; text-align: right" title="Number of options exercisable, end of year">124,399</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zegZseD63ARj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">13.20-<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zdt9X9KjYPHa" title="Option price exercisable, end of year">1,003.20</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; color: Black; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z9Mykpb2QCQ8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life (years)">4.06 years</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; color: Black; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zGc1vLLZsSUh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life (years)">5.98 years</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table>

124399

13.20

1003.20

22.23

128504

13.20

2127.84

25.58

5047

9.68 327.36

57.79

4105

16.76 2127.84

129.88

119352

13.20

2127.84

20.72

124399

13.20

1003.20

22.23

119352

13.20 2127.84

124399

13.20 1003.20

P4Y21D

P5Y11M23D

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Information regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWkNWefe0Xh5" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,474,971</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">0.31-9.68</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">1.72</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,650,017</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="white-space: nowrap; width: 7%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zycM5coCDmZ6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, beginning of year">1.11 – <span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zo3YUK4euDAg" title="Option price outstanding, beginning of year">9.68</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">2.35</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zPCdlU64INS" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">0.47-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zPY5yYMHaoh5" title="Option price, granted">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" style="color: Black; text-align: right" title="Number of options, granted">850,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIDoTWdBMzKi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, granted">0.31 – <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zUhIdoaKAeM5" title="Option price, granted">1.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.51</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" style="color: Black; text-align: right" title="Number of options, forfeited">(60,829</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z3aZJd8umXH6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, forfeited">0.31-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zUQl9ptUUdg7" title="Option price, forfeited">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.98</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" style="color: Black; text-align: right" title="Number of options, forfeited">(25,046</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zAUba1ObnkOl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price, forfeited">1.85 – <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zSdlqpKHm0Vb" title="Option price, forfeited">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSJNjeMW9QCj" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.86</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Option price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSmCOnPdjGs1" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Option price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zJJDhGvlGta9" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znPAgqne0pt2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,814,142</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zepL3rOEQOMh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, end of year">0.31-<span id="xdx_908_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zjopxTDNLZyb" title="Option price outstanding, end of year">9.68</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zj4jXu1T0o88" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.54</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,474,971</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zdVP2wqybK1l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price outstanding, end of year">0.31 – <span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zkyAAoDzVPXl" title="Option price outstanding, end of year">9.68</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" style="color: Black; text-align: right" title="Number of options exercisable, end of year">2,397,474</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">0.31-<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e">327.36</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z5f85g1G8ZKe" style="color: Black; text-align: right" title="Weighted average exercise price exercisable end of year">4.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" style="color: Black; text-align: right" title="Number of options exercisable, end of year">1,916,637</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zg2M3pcSmdEk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Option price exercisable, end of year">0.41 – <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z5R9lpc6C103" title="Option price exercisable, end of year">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zmaoDrlHSq71" style="color: Black; text-align: right" title="Weighted average exercise price exercisable end of year">2.22</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="white-space: nowrap; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zeNewBk1Knul" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life (years)">7.96 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="white-space: nowrap; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zURhk2jYyOBh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life (years)">9.65 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Available for future grants</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvElgq65fgQ7" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Available for future grants">1,210,286</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z5Wcr81lQ78i" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Available for future grants">466,120</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table>

2474971

0.31

9.68

1.72

1650017

1.11

9.68

2.35

400000

0.47 0.47

0.47

850000

0.31 1.71

0.51

60829

0.31 9.68

1.98

25046

1.85 9.68

1.86

2814142

0.31

9.68

1.54

2474971

0.31

9.68

1.72

2397474

0.31 327.36

4.71

1916637

0.41 9.68

2.22

P7Y11M15D

P9Y7M24D

1210286

466120

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Vested stock option activity for employees: Schedule of Vest Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7Cd1KIdDn5l" style="width: 10%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,498,798</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJVgdwD4j8tf" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price beginning of year">4.22</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUg2ivYvgceb" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.11</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zriQd66kX1qh" style="width: 10%; color: Black; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" style="color: Black; text-align: right" title="Number of options, granted">550,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zr3ObctKwXT9" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price granted">0.49</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXJoC9BXIFn1" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) granted">9.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" style="color: Black; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWGVDwzHjio6" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price forfeited">17.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of Options, Expired">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZ2pms0MFVMe" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price expired">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,020,214</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHxOaM5i8Ezj" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price beginning of year">3.01</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zA90DMv1aJ6d" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.86</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRHqEs9Ma7Ai" style="color: Black; text-align: right" title="Aggregate intrinsic value beginning of year">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTlgMLiQwZt1" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price granted">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFOBeabDTBij" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) granted">10.17</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" style="color: Black; text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6OqXjcptC3e" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price forfeited">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ztu0z0sxBWpf" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price expired">41.61</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh3hBmPzQlSi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,408,438</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zeJkOdNtZgz4" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price end of year">2.50</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3DsiWmxBJN9" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.70</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zj2dr0hydFpg" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value ending of year">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV4OkEdjq75j" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options, vested and expected to vest">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z41h4Z90CFra" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price vested and expected to vest">1.90</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZcyMhukria7" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested and expected to vest">6.73</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZHxcS18IPmj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zK2mbJPKD8F8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options exercisable">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6UilfPMmP47" style="font-family: Times New Roman, Times, Serif" title="Weighted average exercise price exercisable">1.90</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSf4JStBmGn6" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) exercisable">6.73</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztYawr6YP4m2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

1498798

4.22

P9Y1M9D

550000

0.49

P9Y8M15D

28584

17.71

2020214

3.01

P8Y10M9D

400000

0.47

P10Y2M1D

7601

9.68

4175

41.61

2408438

2.50

P8Y8M12D

2041772

1.90

P6Y8M23D

2041772

1.90

P6Y8M23D

184000

424999

0.43

768666

575000

1.34

<p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted Average Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average Remaining Contracted Term</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left">Unvested December 31, 2021</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqWTzlDRCDh2" style="width: 13%; text-align: right" title="Number of options unvested, beginning of year">412,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Cz7FkU8xR3" style="width: 13%; text-align: right" title="Weighted average exercise price unvested, beginning of year">4.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ztN57QV8lJf4" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">5.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_znOirm9QawT" style="width: 13%; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRbJ5NwjXDB" style="text-align: right" title="Number of options, granted">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcnLUXLAuHKk" style="text-align: right" title="Weighted average exercise price granted">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zdvphGqGkGqd" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) granted">9.71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlaDllP3aiDd" style="text-align: right" title="Number of options, vested">(541,590</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrnsqmcvQFv4" style="text-align: right" title="Weighted average exercise price vested">1.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKmIlxvixTCa" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">9.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Forfeited</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNrTf165S871" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, forfeited">(28,584</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVRCs30iLe3e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price forfeited">17.71</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested December 31, 2022</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZUpZLtWnau1" style="text-align: right" title="Number of options unvested, beginning of year">392,326</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zioOSWL1jP5d" style="text-align: right" title="Weighted average exercise price unvested, beginning of year">0.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMldkN5sDIEi" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, beginning of year">8.86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNlUfk9xcEIg" style="text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZrSMXNIB9aj" style="text-align: right" title="Number of options, granted">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJewJEr9hh9d" style="text-align: right" title="Weighted average exercise price granted">0.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHF9II4neNva" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) granted">10.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zEjRTabmFlUb" style="text-align: right" title="Number of options, vested">(413,884</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zkce40uIATOk" style="text-align: right" title="Weighted average exercise price vested">1.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNjdm7kIIJga" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) vested">6.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forfeited</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zg0xcWSOHoNi" style="text-align: right" title="Number of options, forfeited">(7,601</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu9xcnDbZEZ5" style="text-align: right" title="Weighted average exercise price forfeited">9.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Expired</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zDczHCvZIb14" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired">(4,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfLv6n2HQAZg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expired">41.61</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Unvested December 31, 2023</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zEyeHBhO90e3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options unvested, ending of year">366,666</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl1beeMK2ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price unvested, ending of year">2.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfl08TREisY2" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) unvested, ending of year">12.44</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJYELYHWcOC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value unvested, ending of year">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

412500

4.15

P5Y10M6D

550000

0.49

P9Y8M15D

541590

1.31

P9Y8M23D

28584

17.71

392326

0.80

P8Y10M9D

400000

0.47

P10Y2M1D

413884

1.90

P6Y8M23D

7601

9.68

4175 41.61

366666

2.13

P12Y5M8D

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Vested stock option activity for non-employees: Schedule of Vest Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEs2LdYztmZb" style="width: 13%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">279,723</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbvLwTLMhI8l" style="width: 13%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">6.12</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zppYmzF5aPvg" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">7.93</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqboIHm0MY2" style="width: 13%; color: Black; text-align: right" title="Aggregate intrinsic value outstanding, beginning of year">—</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8kopK3lZuE6" style="color: Black; text-align: right" title="Number of options, granted">300,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBv1bgg9mBO" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.54</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcLgCkuLQCSg" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), granted">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Exercised</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMmNo7h6qjN1" style="color: Black; text-align: right" title="Number of options, exercised">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNyz8BJgYqH4" style="color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zs7OEELu0YFf" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, forfeited">(568</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMT6Nq6PdVa3" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, forfeited">153.12</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zv5lIy8IM5qg" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">579,155</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBlcxqIXff21" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">3.09</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQPBSsmtmgob" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">8.36</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7JTnEGAAnp5" style="color: Black; text-align: right" title="Aggregate intrinsic value outstanding, beginning of year">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgtIaPy5L8R8" style="color: Black; text-align: right" title="Number of options, granted">360,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0j54vAfy8n7" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.46</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVALSScWmani" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), granted">10.04</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Exercised</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKpeQQtovmZ8" style="color: Black; text-align: right" title="Number of options, exercised">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWc8dBYMEW6a" style="color: Black; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black"> Expired</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFaHI1qW0eg5" style="color: Black; text-align: right" title="Number of options,expired">(653</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zt0TmBEtxrH1" style="color: Black; text-align: right" title="Weighted average exercise price, expired">145.24</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNgnlxZXCMz3" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options, forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zn7GHfNYV2nl" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYSnxO6m4KE8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">885,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBeQWeFrKmj8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">2.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zy2ut5eiqUp2" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years)">9.23</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMU5rcESbhCb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value outstanding, ending of year">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1ahHPoA8eol" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options, vested and expected to vest">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAmU6WfQaq9b" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, vested and expected to vest">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zySeEgubABYa" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years) , vested and expected to vest">10.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_za63Mg8Lwn7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value vested and expected to vest">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUgp16yefPv8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options exercisable, end of year">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zV73ZTvwI9M6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price exercisable, ending of year">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZSFdCo6pXL8" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual term (years), exercisable">10.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEL5mLEjXio3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value exercisable">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

279723

6.12

P7Y11M4D

300000

0.54

P9Y8M4D

568

153.12

579155

3.09

P8Y4M9D

360000

0.46

P10Y14D

653

145.24

53447

1.31

885055

2.02

P9Y2M23D

550055

2.56

P10Y7D

550055

2.56

P10Y7D

90000

191666

0.47

247166

229053

1.08

<p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; color: Black; text-align: left">Unvested December 31, 2021</td><td style="width: 2%; color: Black; text-align: left"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zk92jY3SKqgk" style="width: 13%; color: Black; text-align: right" title="Number of options unvested, beginning of year">97,831</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWcfpTfk0Zi9" style="width: 13%; color: Black; text-align: right" title="Weighted average exercise price unvested, beginning of year">3.89</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zugGZ42TVVFd" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual Term (years) beginning of year">7.82</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_znwVJlgZFZg8" style="width: 13%; color: Black; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Granted</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQKw4QeZCkD1" style="color: Black; text-align: right" title="Number of options granted">300,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzmg1kD0pWD9" style="color: Black; text-align: right" title="Weighted average exercise price granted">0.54</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWufgR11hSCb" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual Term (years) granted">9.68</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Vested</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabNQp6FtYf4" style="color: Black; text-align: right" title="Number of options vested">(229,053</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRrp4QjNHUK4" style="color: Black; text-align: right" title="Weighted average exercise price vested">0.82</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFqYIWTqJU11" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options forfeited">(1,989</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Unvested December 31, 2022</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztUgztRmpnqe" style="color: Black; text-align: right" title="Number of options unvested, beginning of year">166,789</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCfwWbqdgDK2" style="color: Black; text-align: right" title="Weighted Average Exercise Price Number of options unvested, beginning of year">4.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zmfc5mHCPaR5" style="font-family: Times New Roman, Times, Serif" title="Average Remaining Contractual Term (years) unvested, beginning of year">9.49</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zg20zTtksb9e" style="color: Black; text-align: right" title="Aggregate intrinsic value unvested, beginning of year">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Granted</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0NWtJezinqf" style="color: Black; text-align: right" title="Number of options granted">360,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDYxe9GPcc62" style="color: Black; text-align: right" title="Weighted average exercise price granted">0.46</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoIHS4NGC1Od" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual Term (years) granted">10.18</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Vested</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaUTXaP94rH7" style="color: Black; text-align: right" title="Number of options vested">(137,565</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrkzKvozb3gf" style="color: Black; text-align: right" title="Weighted average exercise price vested">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTNTRx44LZsh" style="font-family: Times New Roman, Times, Serif" title="AWeighted average remaining contractual Term (years) vested">9.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expired</td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaZW787Juujf" style="color: Black; text-align: right" title="Number of options expired">(776</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuk3FxuFZEh6" style="color: Black; text-align: right" title="Weighted average exercise price expired">145.24</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcJ6qQlusKrg" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of options forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTsjJ5Vjycl6" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price forfeited">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unvested December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zQ2yciXIcXrb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options ending of year">335,001</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zveX3FSVK0o7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price ending of year">1.83</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbifrIOXXzVe" style="font-family: Times New Roman, Times, Serif" title="Weighted average remaining contractual Term (years) uvested, ending of year">10.70</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvkmLL21RoE9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate intrinsic value unvested, ending of year">—</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>

97831

3.89

P7Y9M25D

300000

0.54

P9Y8M4D

229053

0.82

1989

166789

4.05

P9Y5M26D

360000

0.46

P10Y2M4D

137565

0.47

P9Y5M19D 776 145.24

53447

1.31

335001

1.83

P10Y8M12D

243000

954000

294000

217000

<p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Information regarding warrants outstanding and exercisable into shares of common stock is summarized below: Schedule of Warrants Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: justify">Outstanding, beginning of year </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB21PsJgzOzh" style="width: 8%; color: Black; text-align: right" title="Number of outstanding, beginning of year">226,610</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 8%; color: Black; text-align: right">$ <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjDTxWKhK3th" title="Warrant price beginning of the year">0.99-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAG5jyi4nDck" title="Warrant price beginning of the year">132.00</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3psSq5Dvm96" style="width: 8%; color: Black; text-align: right" title="Number of outstanding, beginning of year">294,939</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 8%; color: Black; text-align: right">$<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zgV7v3XqgwN" title="Warrant price beginning of the year">0.99 – <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zbiDReT7UGcc" title="Warrant price beginning of the year">469.92</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">15.19</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zndHzhSjjuf3" style="color: Black; text-align: right" title="Number of outstanding, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPjxUpQ74ohf" style="color: Black; text-align: right" title="Warrant price granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGL8jDnh9xA2" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyH1Cc623fNk" style="color: Black; text-align: right" title="Number of outstanding, granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv2hDEBTlwMh" style="color: Black; text-align: right" title="Warrant price granted">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaMnmF2kIfN6" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, granted">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Expired</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfHx7AfC7Tij" style="color: Black; text-align: right" title="Number of outstanding, expired">(74,450</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSAJbBHEaA9" style="font-family: Times New Roman, Times, Serif" title="Warrant price expired">17.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxUQiCUef034" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, expired">17.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW7b5bVDXTth" style="color: Black; text-align: right" title="Number of outstanding, expired">(68,215</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23CecWIDAZ3" style="font-family: Times New Roman, Times, Serif" title="Warrant price expired">469.92</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z04DjcMYP5c8" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, expired">469.92</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQm1H88DK8oe" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of outstanding, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zConGTCMYuO8" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Warrant price exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZOmF4KMaBF2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, exercised">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbDzqKntwkl2" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of outstanding, exercised">(114</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWKIwR0r00bk" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Warrant price exercised">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM03d6qDVpj" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, exercised">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQTQ7OTCKga6" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of outstanding, end of year">152,160</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">$ <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zAnLIGdZmAib" title="Warrant price end of the year">0.99-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z3vCgp9Au7va" title="Warrant price end of the year">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Ft54Be4PVf" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">8.03</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQPpCsmELAqd" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Number of outstanding, end of year">226,610</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: Black; text-align: right">$ <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zhn74WMjmbtc" title="Warrant price end of the year">0.99-<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zZJ2dT7hECO" title="Warrant price end of the year">132.00</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1pt solid; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6SQeeslPyf5" style="border-bottom: Black 1pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">9.10</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zul2htOWCJ2g" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of outstanding, exercisable">152,160</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">$ <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWbaUGh8wkx9" title="Warrant price exercisable">0.99-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zdilkZuTsu38" title="Warrant price exercisable">8.80</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHuRrGG3YpL1" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price exercisable">8.03</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9eQX3lJjcle" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of outstanding, exercisable">226,610</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">$ <span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zakb5muf7gDl" title="Warrant price exercisable">0.99-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpoxQoeCYfch" title="Warrant price exercisable">132.00</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRfAmIe0oaP3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price exercisable">9.10</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Weighted average remaining contractual life</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1UI621XbpC7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life">.75 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoTdSyGyrkXj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Weighted average remaining contractual life">.94 years</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Years exercisable</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJxcsQo69APg" style="font-family: Times New Roman, Times, Serif" title="Years exercisable">2024</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zUpRsQlGD8Gf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black" title="Years exercisable">2023-<span id="xdx_904_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5nXjHBfCTf5" title="Years exercisable">2024</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td></tr> </table>

226610

0.99 132.00 9.10

294939

0.99 469.92 15.19

74450

17.05 17.05

68215

469.92 469.92

114

8.80 8.80

152160

0.99 8.80 8.03

226610

0.99 132.00 9.10 152160 0.99 8.80 8.03 226610 0.99 132.00 9.10 P0Y9M P0Y11M8D 2024 2023 2024

114

(7) Segment and Related Information The Company operates in one segment, which performs research and development activities related to Ampligen and other drugs under development. The Company’s revenues for the two-year period ended December 31, 2023, were earned in the United States. All assets are maintained in the United States of America.

(8) Research, Consulting and Supply Agreements The Company has entered into research, consulting and supply agreements with third party service providers to perform research and development activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred. During the year ended December 31, 2023, research and development expenses were comprised of: clinical studies ($6,014,000), manufacturing and engineering ($3,220,000), quality control ($1,271,000) and regulatory ($434,000). During the year ended December 31, 2022, research and development expenses were comprised of: clinical studies ($4,070,000), manufacturing and engineering ($1,241,000), quality control ($1,236,000) and regulatory ($443,000). The following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related to research and development costs during the year ended December 31, 2023. Amarex Clinical Research LLC Amarex is the principal administrator of several of AIM’s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research LLC (“Amarex”). During the year ended December 31, 2023 and 2022, the Company incurred approximately $4,290,000 and $2,272,000, respectively, related to these ongoing agreements: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pancreatic Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex’s management of the study will cost approximately $8,400,000. This estimate includes pass-through costs of approximately $1,000,000 and excludes certain third-party and investigator costs and escalations necessary for study completion. AIM anticipates that the study will take approximately 4.6 years to complete.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zEogaZmww6xe">600,000 related to this agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zRA9HhWySi2b">1,691,000 related to this agreement.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Post-COVID Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $6,400,000, which includes pass through costs of approximately $125,000, investigator costs estimated at about $4,400,000, and excludes certain other third-party costs and escalations. During 2023, the original work order increased to approximately $6,600,000 for the addition of patient reported outcome (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated with the ePRO system and additional safety monitoring services as well as changes to study documentation (such as protocol amendments) which resulted in additional IND submissions to FDA. This study was effectively concluded in 2023.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zX4oZsJX0Xcg">3,690,000 related to this agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zBWSLzE4RDt">581,000 related to this agreement.</td></tr> </table> Jubilant HollisterStier Jubilant HollisterStier (“Jubilant”) is AIM’s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen® for the Company. Since the 2017 engagement of Jubilant, two lots of Ampligen consisting of more than 16,000 units were manufactured and released in the year 2018. The first lot was designated for human use in the United States in the cost recovery CFS program and for expanded oncology clinical trials. The second lot has been designated for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant manufactured additional two lots of Ampligen in December 2019 and January 2020. In March 2023, the Company ordered an additional 27,900 vials from Jubilant at a cost of approximately $1,432,000. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zfI7t5QWlnMa">1,432,000 related to this agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zCKeu8FivXJ">79,000 related to this agreement.</td></tr> </table> Sterling Pharma Solutions In 2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (“Sterling”) for the manufacture of the Company’s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--PharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zKzuIfnLYHIk">363,000 related to this agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr> </table> Erasmus In December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM’s limited responsibilities are limited to providing Ampligen. Additionally, AIM agreed to provide a grant of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20221201__20221231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zrZLNisgBPx">200,000 for the study. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JjointClinicalStudyAgreementMember_zbzGQ71Oq9Yg">100,000 pursuant to the Grant Agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr> </table> Azenova Sales International In October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development services for AIM’s Ampligen product for solid tumors for a 12 month term that is extendable upon the agreement of the parties. In exchange for its services, Azenova will receive a fixed monthly retainer of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zDtRuFC8pDte">30,000 per month in addition to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zoUQauZAXSz5">360,000 stock options that vest monthly. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2023, the Company incurred approximately $75,000 related to this agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr> </table> Alcami In September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging component. The agreement called for fixed costs of approximately $30,000 upon completion of the study and issue of the final report, along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received in December 2023. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2023, the Company incurred approximately $65,000 of lab services from Alcami.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $18,000 of lab services from Alcami.</td></tr> </table>

6014000

3220000

1271000

434000

4070000

1241000

1236000

443000

4290000

2272000

8400000

1000000

P4Y7M6D

600000

1691000

6400000

125000

4400000

6600000

3690000

581000

16000 27900

1432000

79000

363000

200000

100000

30000

360000

75000

30000

65000

18000

(9) 401(k) Plan AIM has a defined contribution plan, entitled the AIM ImmunoTech Employees 401(k) Plan and Trust Agreement (the “401(k) Plan”). AIM’s full-time employees are eligible to participate in the 401(k) Plan following 61 days of employment. Subject to certain limitations imposed by federal tax laws, participants are eligible to contribute up to 15% of their salary (including bonuses and/or commissions) per annum. Participants’ contributions to the 401(k) Plan may be matched by us at a rate determined annually by the Board. Each participant immediately vests in his or her deferred salary contributions as well as the Company’s safe harbor contributions. A 6% safe harbor matching contribution by us was reinstated effective January 1, 2021. For the year ended December 31, 2023 and 2022, the Company’s matching contributions were approximately $162,000 and $122,000, respectively

0.15

0.06

162000

122000

(10) Employment Agreements The Company had contractual agreements with Named Executive Officers (“NEO”) in 2023, and 2022. The aggregate annual base compensation for these NEO under their respective contractual agreements for 2023 and 2022 was $<span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zj0ShGkuJnL1">1,275,000 and $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zaEP2bBxhiGd">1,275,000, respectively. In addition, certain of these Officers were entitled to receive performance bonuses of up to <span id="xdx_90C_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zAWrRcxlY5Ya">25% or <span id="xdx_902_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_ziu4G3VqCNwd">20% of their respective annual base salary, at the sole discretion of the Compensation Committee of the Board of Directors. For the years ended December 31, 2023 and 2022, Officers’ bonuses were $<span id="xdx_903_ecustom--Bonus_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zEMZSOc8AYE5">450,000, to be deferred and paid in 2024 and $<span id="xdx_90B_ecustom--Bonus_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_z1JvkmqZRr9h">450,000, respectively. In 2023, equity was granted as a form of compensation to these Officers. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLuhZd8cUGIg">300,000 <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zPof6dwOlau" title="Options term::XDX::P10Y">ten-year options to purchase common stock with an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5z5Hbpc0Nte">0.47 per share to vest in <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zP3lUqpy1hlg">one year to Thomas K. Equels, Chief Executive Officer. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">b. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zC6zjeGF8sLe">100,000 <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zPvN4XXMJRph" title="Options term::XDX::P10Y">ten-year options to purchase common stock with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zTrS2M1Re0Ai">0.47 per share which vest in <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_ztOxwIqUCeed">one year to Peter Rodino, Chief Operating Officer and General Counsel.</td></tr> </table> The Company recorded stock compensation expense of approximately $14,000 during the year ended December 31, 2023 with regard to these issuances to Officers Equels and Rodino. In 2022, equity was granted as a form of compensation to these Officers. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z6KkeQwFNM9l">300,000 <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z0lyHtnzDHGk" title="Options term::XDX::P10Y">ten-year options to purchase common stock with an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zlND1tOnooGc">0.41 per share to vest in <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLAigI8Ixqb6">one year to Thomas K. Equels, Chief Executive Officer. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">d. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zqR0Vn4Va4Ni">150,000 <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zUSKmi25I5td" title="Options term::XDX::P10Y">ten-year options to purchase common stock with exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MinimumMember_zVGM4kglJob6">0.41 to $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MaximumMember_z0pDSSJI41T5">0.70 per share which vest in <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zW8O62SfRcNh">one year to Peter Rodino, Chief Operating Officer and General Counsel.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">e. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_zF2JjGbqRn9h">50,000 <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z3vRF30LHOv5" title="::XDX::P10Y">ten-year options to purchase common stock with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z3sSALWeLDHh">0.70 per share which vest in <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_ztrwY3O2VUSk">one year to Ellen Lintal, former Chief Financial Officer.</td></tr> </table> The Company recorded stock compensation expense of approximately $107,000 during the year ended December 31, 2023 with regard to these issuances to Officers Equels, Rodino, and former Officer Lintal.

1275000

0.25

0.20

450000 450000

300000

0.47

P1Y

100000

0.47

P1Y

14000

300000

0.41

P1Y

150000

0.41

0.70

P1Y

50000

0.70

P1Y

107000

(11) Leases The Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 to 5 years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $1,000 to $17,000. Certain leases include additional renewal options ranging from 1 to 5 years. AIM has classified all of its leases as operating leases. As of December 31, 2023 and 2022, the balance of the right of use assets was $697,000 and $829,000, respectively, and the corresponding operating lease liability balance was $718,000 and $837,000, respectively. Right of use assets are recorded net of accumulated amortization of $363,000 and $158,000 as of December 31, 2023 and 2022, respectively. AIM recognized rent expense associated with these leases are follows: Schedule of AIM Recognized Rent Expense Associated with Operating Lease <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease costs:</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td> <td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">128</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Short-term and variable lease costs</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">335</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">211</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify">Total lease costs</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Classification of lease costs</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: justify">Research & development</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">498</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Lease cost</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company’s leases have remaining lease terms between 3 and 44 months. As of December 31, 2023 and 2022, the weighted-average remaining term was 41 and 43 months, respectively. The Company’s weighted average incremental borrowing rate for its leases was 10% as of December 31, 2023 and 2022, respectively. Future minimum payments as of December 31, 2023, are as follows: Schedule of Operating Lease Future Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td> </td> <td colspan="2" id="xdx_494_20231231_zcJjykldx2C"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zcQoyXDTKizh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 35%; text-align: right">279</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zUTkyUJEjyLj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year one</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">279</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zxhJVNND3Phh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zBEU7k4ioIt6" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_ztgNqoqncVoh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zqX7qSTmHFo7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_zP0NASeBUUzi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_zv3CIdC0rkvc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_zT2tLpNOjtb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_zOaR5AlnT9Dg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year five</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z1uurCz7jkyc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zr9CD4Zr4LQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">718</td><td style="padding-bottom: 2.5pt; text-align: justify"> </td></tr> </table>

P1Y

P5Y

1000

17000

P1Y

P5Y

697000

829000

718000

837000

363000 158000

AIM recognized rent expense associated with these leases are follows: Schedule of AIM Recognized Rent Expense Associated with Operating Lease <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease costs:</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td> <td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">128</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Short-term and variable lease costs</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">335</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">211</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify">Total lease costs</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Classification of lease costs</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: justify">Research & development</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">498</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Lease cost</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

288

128

335

211

623

339

498

220

125

119

125

119

623

339

P3M

P44M

P41M

P43M

0.10

Future minimum payments as of December 31, 2023, are as follows: Schedule of Operating Lease Future Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td> </td> <td colspan="2" id="xdx_494_20231231_zcJjykldx2C"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zcQoyXDTKizh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 35%; text-align: right">279</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zUTkyUJEjyLj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year one</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">279</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zxhJVNND3Phh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zBEU7k4ioIt6" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_ztgNqoqncVoh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zqX7qSTmHFo7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_zP0NASeBUUzi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_zv3CIdC0rkvc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_zT2tLpNOjtb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_zOaR5AlnT9Dg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Year five</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z1uurCz7jkyc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zr9CD4Zr4LQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">718</td><td style="padding-bottom: 2.5pt; text-align: justify"> </td></tr> </table>

279000

229000

200000

133000

123000

718000

(12) Income Taxes (FASB ASC 740 Income Taxes) The Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material change to the Company’s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception of net operating losses and research and development credits generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration. As of December 31, 2023, the Company has approximately $166,300,000 of Federal net operating loss carryforwards (expiring in the years 2023 through 2038), and $103,300,000 of Federal net operating loss carryforwards with no expiration date, both of which have been limited by Internal Revenue Code Section 382, available to offset future federal taxable income. The Company has approximately $28,800,000 of New Jersey state net operating loss carryforwards (expiring in 2044). The Company has approximately $82,500,000 of Florida state net operating loss carryforwards with no expiration date to offset future Florida taxable income. The Company has approximately $3,600,000 of Belgium net operating loss carryforwards with no expiration date to offset future taxable income In December 2023, the Company effectively sold $14,156,000 of its New Jersey state net operating loss carryforward and $38,600 in R&D credits for the year 2022 for approximately $1,313,000. The utilization of certain state net operating loss carryforwards may be subject to annual limitations. With no tax due for the foreseeable future, the Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at this time. Under the Tax Reform Act of 1986, the utilization of a corporation’s net operating loss carryforward is limited following a greater than 50% change in ownership. As noted above, due to the Company’s prior and current equity transactions, some of the Company’s net operating loss carryforwards are subject to an annual limitation generally determined by multiplying the value of the Company on the date of the ownership change by the federal long-term tax-exempt rate. Any unused annual limitation may be carried forward to future years for the balance of the net operating loss carryforward period. Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting purposes and the carrying amounts used for income tax purposes. In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. With the exception of net operating losses generated in New Jersey which can be surrendered for 80% of their value, due to the uncertainty of the Company’s ability to realize the benefit of the deferred tax asset, the remainder of our deferred tax assets are fully offset by a valuation allowance at December 31, 2023 and 2022. The components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an immaterial deferred tax error of approximately $1.4 million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022, consist of the following: Schedule of Components of Net Deferred Tax Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify">Deferred tax assets:</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zvrKCcT2BaKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Net operating losses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,674</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Research and Development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,647</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Amortization & depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">R&D credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">744</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,479</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,472</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,958</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(36,816</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(30,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn3n3_mtDTALNzkn6_zCZ6TEC4uKf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,604</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred tax assets are included within other assets in the accompanying Consolidated Balance Sheets. The benefits of deferred tax assets are included within the gain from sale of income tax operating losses in the accompanying Consolidated Statements of Operations and Comprehensive Loss. The Company’s deferred tax asset estimates the projected sale of 2023 and 2022 New Jersey state operating losses to be sold in the subsequent year, respectively. Rate Reconciliation Reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands): Schedule of Effective Tax Rate and Statutory Tax Rate <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Pre Tax Book Loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" style="width: 16%; text-align: right" title="Pre Tax Book Loss">(28,962</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Federal Rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" style="text-align: right" title="Federal Rate">(6,082</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" style="text-align: right" title="Federal Rate">21.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State Taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" style="text-align: right" title="State Taxes">(2,244</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" style="text-align: right" title="State Taxes">7.75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Perms</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right" title="Other Perms">(83</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right" title="Other Perms">0.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RTP</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" style="text-align: right" title="RTP">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" style="text-align: right" title="RTP">0.03</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Income Tax Income</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right" title="Income Tax Income">(479</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right" title="Income Tax Income">1.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>State Rate Change</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right" title="State Rate Change">618</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right" title="State Rate Change">-2.13</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>R&D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right" title="R&D">(272</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right" title="R&D">0.94</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>State NOL</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right" title="State NOL">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right" title="State NOL">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>NJ NOL True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right" title="NJ NOL True Up">1,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right" title="NJ NOL True Up">-3.88</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Compensation True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right" title="Stock Compensation True Up">(1,347</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right" title="Stock Compensation True Up">4.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fixed Assets True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right" title="Fixed Assets True Up">925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right" title="Fixed Assets True Up">-3.19</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" style="text-align: right" title="Other">(22</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" style="text-align: right" title="Other">0.08</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">NOL Refund VA True Up</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1pt solid; text-align: right" title="NOL Refund VA True Up">486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1pt solid; text-align: right" title="NOL Refund VA True Up">-1.68</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right" title="Other"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right" title="Statutory Other"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation Allowance">7,385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" style="border-bottom: Black 1pt solid; text-align: right" title="Statutory Valuation Allowance">-25.50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Statutory Total">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

166300000

103300000

28800000

82500000

3600000

14156000

38600

1313000

The components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an immaterial deferred tax error of approximately $1.4 million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022, consist of the following: Schedule of Components of Net Deferred Tax Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify">Deferred tax assets:</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zvrKCcT2BaKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Net operating losses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,674</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Research and Development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,647</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Amortization & depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">R&D credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">744</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,479</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,472</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,958</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(36,816</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(30,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn3n3_mtDTALNzkn6_zCZ6TEC4uKf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,604</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1400000

25114000

19674000

3517000

7647000

6791000 2342000

1376000

744000

137000

77000

6000 2000

1479000

1472000

38420000

31958000

36816000

30840000

1604000

1118000

Reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands): Schedule of Effective Tax Rate and Statutory Tax Rate <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Pre Tax Book Loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" style="width: 16%; text-align: right" title="Pre Tax Book Loss">(28,962</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Federal Rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" style="text-align: right" title="Federal Rate">(6,082</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" style="text-align: right" title="Federal Rate">21.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State Taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" style="text-align: right" title="State Taxes">(2,244</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" style="text-align: right" title="State Taxes">7.75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Perms</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right" title="Other Perms">(83</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right" title="Other Perms">0.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RTP</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" style="text-align: right" title="RTP">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" style="text-align: right" title="RTP">0.03</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Income Tax Income</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right" title="Income Tax Income">(479</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right" title="Income Tax Income">1.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>State Rate Change</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right" title="State Rate Change">618</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right" title="State Rate Change">-2.13</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>R&D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right" title="R&D">(272</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right" title="R&D">0.94</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>State NOL</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right" title="State NOL">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right" title="State NOL">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>NJ NOL True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right" title="NJ NOL True Up">1,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right" title="NJ NOL True Up">-3.88</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Compensation True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right" title="Stock Compensation True Up">(1,347</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right" title="Stock Compensation True Up">4.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fixed Assets True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right" title="Fixed Assets True Up">925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right" title="Fixed Assets True Up">-3.19</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" style="text-align: right" title="Other">(22</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" style="text-align: right" title="Other">0.08</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">NOL Refund VA True Up</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1pt solid; text-align: right" title="NOL Refund VA True Up">486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1pt solid; text-align: right" title="NOL Refund VA True Up">-1.68</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right" title="Other"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right" title="Statutory Other"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation Allowance">7,385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" style="border-bottom: Black 1pt solid; text-align: right" title="Statutory Valuation Allowance">-25.50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Statutory Total">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

-28962000

-6082000

0.210

-2244000

0.0775

-83000

0.0029

-8000 0.0003

-479000

0.0165

618000

-0.0213

272000

0.0094

0.0000 1123000 -0.0388

-1347000

0.0465

925000 -0.0319

-22000

0.0008 486000 -0.0168

7385000

-0.2550

0.000

(13) Certain Relationships and Related Transactions The Company has an employment agreement with its NEOs and has granted its NEOs and directors options to purchase its common stock. Please see details of these Employment Agreements in Note 10 - Employment Agreements.

(14) Concentrations of Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents, investments and accounts receivable. The Company places its cash with high-quality financial institutions and, at times, such amounts in non-interest-bearing accounts may be in excess of Federal Deposit Insurance Corporation insurance limits. There were no credit-based sales for 2023 and 2022. There are a limited number of suppliers in the United States and abroad available to provide the raw and packaging materials/reagents for use in manufacturing Ampligen and Alferon N Injection. At present, the Company does not have any agreements with third parties for the supply of any of these materials or it is relying on a limited source of reagent suppliers necessary for the manufacture of Alferon N Injection. Jubilant HollisterStier LLC has manufactured batches of Ampligen for us pursuant to purchase orders. The Company anticipates that additional orders will be placed upon approved quotes and purchase orders provided by us to Jubilant. On December 22, 2020, it added Pharmaceutics International Inc. (“Pii”) as a “Fill & Finish” provider to enhance our capacity to produce the drug Ampligen. This addition amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment the Company’s existing fill and finish capacity. If the Company is unable to place adequate acceptable purchase orders with Jubilant or Pii in the future at acceptable prices upon acceptable terms, it will need to find another manufacturer. The costs and availability of products and materials the Company would need for the production of Ampligen are subject to fluctuation depending on a variety of factors beyond our control, including competitive factors, changes in technology, ownership of intellectual property, FDA and other governmental regulations. There can be no assurance that the Company will be able to obtain such products and materials on terms acceptable to it or at all. Currently, the Alferon N Injection manufacturing process is on hold and there is no definitive timetable to restart production. If the Company is unable to acquire FDA approvals related to the manufacturing process and/or final product of new Alferon N Injection inventory or contract with a CMO, its operations most likely will be materially and/or adversely affected. In light of these contingencies, there can be no assurances that the approved Alferon N Injection product will be returned to production on a timely basis, if at all, or that if and when it is again made commercially available, it will return to prior sales levels.

(15) Fair Value The Company complies with the provisions of FASB ASC 820 “Fair Value Measurements” for its financial and non-financial assets and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">3. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of September 30, 2023, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. </td></tr> </table> The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zhuz119vAu8a" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" style="text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" style="text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_z0EDhfJUfyW8" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" style="text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" style="text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td></tr> </table> The Company’s cash balances are representative of their fair values as these balances are comprised of deposits available on demand. For certain instruments, including funds receivable from New Jersey net operating loss, accounts payable and accrued expenses, it was estimated that the carrying values approximated the fair value due to the short-term maturities of these instruments (Level 1). The Company also has certain redeemable warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the redeemable warrants (“Redeemable Warrants”) related to the Company’s March 2019 common stock and warrant issuance, are calculated using a Monte Carlo Simulation (Level 3). The Company recomputes the fair value of the Redeemable Warrants at the issuance date and the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different. <p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.31</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.47</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.67</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z4FTr6b6ddGl" style="font-family: Times New Roman, Times, Serif" title="Expected holding period">.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgwirfusIac2" style="font-family: Times New Roman, Times, Serif" title="Expected holding period">1.19</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> </table> The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(i) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-Free Interest Rate. The risk-free interest rates for the Warrants are based on U.S. Treasury constant maturities for periods commensurate with the remaining expected holding periods of the warrants.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(ii) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Holding Period. The expected holding period represents the period of time that the Warrants are expected to be outstanding until they are exercised. The Company utilizes the remaining contractual term of the Warrants at each valuation date as the expected holding period.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(iii) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Volatility. Expected stock volatility is based on daily observations of the Company’s historical stock values for a period commensurate with the remaining expected holding period on the last day of the period for which the computation is made.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(iv) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Dividend Yield. Expected dividend yield is based on the Company’s anticipated dividend payments over the remaining expected holding period. As the Company has never issued dividends, the expected dividend yield is 0% and this assumption will be continued in future calculations unless the Company changes its dividend policy.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(v) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Probability of a Fundamental Transaction. The possibility of the occurrence of a Fundamental Transaction triggering a Put right is extremely remote. As discussed above, a Put right would only arise if a Fundamental Transaction 1) is an all cash transaction; (2) results in the Company going private; or (3) is a transaction involving a person or entity not traded on a national securities exchange. The Company believes such an occurrence is highly unlikely because:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company only has one product that is FDA approved but is currently not available for commercial sales.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">2. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company will have to perform additional clinical trials for FDA approval of its flagship product.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">3. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Industry and market conditions continue to include uncertainty, adding risk to any transaction.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">4. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Available capital for a potential buyer in a cash transaction continues to be limited.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">5. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research & Development.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">6. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">7. </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer.</td></tr> </table> <p id="xdx_89C_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z7V0wDaPijBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Potential Liability <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: center">Low</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_902_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_znCIcAbE27Fg" style="font-family: Times New Roman, Times, Serif" title="Percentage of probability">0.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Medium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zbI2jq7kSGH2" style="font-family: Times New Roman, Times, Serif" title="Percentage of probability">1.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">High</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zrbe9G1esb2h" style="font-family: Times New Roman, Times, Serif" title="Percentage of probability">5.0</td><td style="text-align: left">%</td></tr> </table> The Monte Carlo Simulation has incorporated a 5.0% probability of a Fundamental Transaction to date for the life of the securities. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(vi) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Timing of Announcement of a Fundamental Transaction. As the Company has no specific expectation of a Fundamental Transaction, for reasons elucidated above, the Company utilized a discrete uniform probability distribution over the Expected Holding Period to model in the potential announcement of a Fundamental Transaction occurring during the Expected Holding Period.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(vii) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected 100 Day Volatility at Announcement of a Fundamental Transaction. An estimate of future volatility is necessary as there is no mechanism for directly measuring future stock price movements. Daily observations of the Company’s historical stock values for the 100 days immediately prior to the Warrants’ grant dates, with a floor of 100%, were utilized as a proxy for the future volatility.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(viii) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction. The Company utilized a risk-free interest rate corresponding to the forward U.S. Treasury rate for the period equal to the time between the date forecast for the public announcement of a Fundamental Transaction and the Warrant expiration date for each simulation.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(ix) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Time Between Announcement and Consummation of a Fundamental Transaction. The expected time between the announcement and the consummation of a Fundamental Transaction is based on the Company’s experience with the due diligence process performed by acquirers and is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional period to reflect the delay Warrant Holders would experience in receiving the proceeds of the Put.</td></tr> </table> While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input change from period to period (e.g., the actual historical prices input for the relevant period). The carrying amount and estimated fair value of the above Warrants was approximately $0 at December 31, 2023 and 2022.

The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zhuz119vAu8a" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" style="text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" style="text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_z0EDhfJUfyW8" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" style="text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" style="text-align: right" title="Marketable securities">—</td><td style="text-align: left"> </td></tr> </table>

4805000

7631000

25180000

7137000

<p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.31</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.47</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.67</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z4FTr6b6ddGl" style="font-family: Times New Roman, Times, Serif" title="Expected holding period">.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgwirfusIac2" style="font-family: Times New Roman, Times, Serif" title="Expected holding period">1.19</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> </table>

0.44

0.31

8.80

5.47

4.67

P0Y2M8D

P1Y2M8D

0 <p id="xdx_89C_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z7V0wDaPijBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Potential Liability <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: center">Low</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_902_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_znCIcAbE27Fg" style="font-family: Times New Roman, Times, Serif" title="Percentage of probability">0.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Medium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zbI2jq7kSGH2" style="font-family: Times New Roman, Times, Serif" title="Percentage of probability">1.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">High</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zrbe9G1esb2h" style="font-family: Times New Roman, Times, Serif" title="Percentage of probability">5.0</td><td style="text-align: left">%</td></tr> </table> 0.005 0.010 0.050 0.050 1

(16) Contingencies Because litigation is inherently unpredictable, assessing contingencies related to litigation is a complex process involving highly subjective judgment about potential outcomes of future events. When evaluating litigation contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the availability of appellate remedies, insurance coverage related to the claim or claims in question, the presence of complex or novel legal theories, and the ongoing discovery and development of information important to the matter. In addition, damage amounts claimed in litigation against the Company may be unsupported, exaggerated, or unrelated to possible outcomes, and as such are not meaningful indicators of the Company’s potential liability or financial exposure. Accordingly, the Company reviews the adequacy of accruals and disclosures each quarter in consultation with legal counsel, and it assesses the probability and range of possible losses associated with contingencies for potential accrual in the condensed consolidated financial statements. However, the ultimate resolution of litigated claims may differ from the Company current estimates. In the normal course of business, there are various claims in process, matters in litigation, and other contingencies, certain of which are covered by insurance policies. When a loss is probable, we record an accrual based on the reasonably estimable loss or range of loss. We do not record liabilities for reasonably possible loss contingencies but do disclose a range of reasonably possible losses if they are material and we are able to estimate such a range. If we cannot provide a range of reasonably possible losses, we explain the factors that prevent us from determining such a range. Historically, adjustments to our estimates have not been material. While it is not possible to predict the outcome of these suits, legal proceedings, and claims with certainty, management is of the opinion that adequate provision for potential losses associated with these matters has been made in the financial statements and that the ultimate resolution of any one of these matters will not have a material adverse effect on the Company’s financial position and results of operations. A significant increase in the number of these claims, or one or more successful claims resulting in greater liabilities than the Company currently anticipates, could materially and adversely affect the Company’s business, financial condition, results of operations, and cash flows.

(17) Subsequent Events On February 16, 2024, the Company entered into a Note Purchase Agreement with an unrelated party raising $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20240216__20240216__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__custom--DebtIstrumentAxis__custom--UnsecuredPromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zPd1bN9HZ8Q7">2,500,000 in net proceeds from the sale of an unsecured promissory Note. On March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement with an unrelated party, pursuant to which this party committed to purchase up to $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240328__20240328__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zph9uGpTxlja">15,000,000 of common stock of the Company for a period of 24 months from the date of the agreement. In March 2024, the Company sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zlBh2vNi0Dkc">204,547 and <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zZhZfO9CzpT4">38,462 shares of its common stock at prices of $0.33 and $0.39 per share, respectively, under the Employees and Directors Purchase Plan.

2500000

15000000

204547

38462

0.33

0.39